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INTRODUCTION 
 
 
Angiogenesis   
 
Formation of new blood vessels - might one day be manipulated to treat disorders 
from cancer to heart disease. Blood vessels play surprisingly central roles in many serious 
chronic disorders. Blood vessels constitute the first organ in the embryo and form the largest 
network in our body but, sadly, are also often deadly. When dysregulated, the formation of 
new blood vessels contributes to numerous malignant, ischemic, inflammatory, infectious and 
immune disorders.  
In mammalian development, a vascular network is formed throughout the body, 
except in avascular tissues (e.g., cornea and intervertebral disks), to meet the tissue 
requirements for oxygen and nutrients. Three major processes are necessary to form a 
complete vascular network- vasculogenesis, angiogenesis and vascular remodeling. 
Vasculogenesis denotes de novo blood vessel formation, in which vascular precursor 
cells (angioblasts) migrate to sites of vascularization, differentiate into endothelial cells and 
coalesce to form the initial vascular plexus.  
Angiogenesis refers to the budding of new capillary branches from existing blood 
vessels. Vascular remodeling describes a later phase when a newly formed vessel increases 
its luminal diameter in response to increased blood flow and acquires identity as an artery, 
vein or capillary.  
Once these three processes are completed during postnatal development, adult 
vasculature is stable and rarely proliferates under physiological conditions. However, in 
pathological situations such as ocular neovascular diseases and cancer, existing vessels again 
start to grow to meet the abnormal requirements for oxygen and nutrients of the 
pathologically expanding tissues. 
Chapter – 1                                                                                                Introduction 
 
Department of Pharmacology                                               The Erode College of Pharmacy  
2 
 
 
Figure.1 Blood vessels 
The angiogenesis process 
 Angiogenesis occurs as an orderly cascade of molecular and cellular events 
 
Figure.2 Angiogenesis- cascade of events 
Cascade of events in angiogenesis 
1. Angiogenic growth factors bind to their receptors on the surface of endothelial cells in 
pre-existing venules (parent vessels). 
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2. Growth factor-receptor binding activates signalling pathways within endothelial cells. 
3. Activated endothelial cells release proteolytic enzymes that dissolve the basement   
membrane surrounding parent vessels. 
4. Endothelial cells proliferate and sprout outward through the basement membrane. 
5. Endothelial cells migrate into the wound bed using cell surface adhesion molecules 
known as integrins (αVβ3, αVβ5, and α5β1). 
6. At the advancing front of sprouting vessels, enzymes known as matrix 
metalloproteinases (MMPs) dissolve the surrounding tissue matrix. 
7. Vascular sprouts form tubular channels which connect to form vascular loops. 
8. Vascular loops differentiate into afferent (arterial) and efferent (venous) limbs. 
9. New blood vessels mature by recruiting mural cells (smooth muscle cells and 
pericytes) to stabilize the vascular architecture. 
10. Blood flow begins in the mature stable vessel. 
 These complex growth factor-receptor, cell-cell, and cell-matrix interactions 
characterize the angiogenesis process, regardless of the inciting stimuli or its location in 
the body. 
Angiogenesis in disease 
In many serious disease states, angiogenesis is dysregulated. Angiogenesis-dependent 
diseases result when new blood vessels either grow excessively or insufficiently. 
 
        Figure.3 Angiogenesis in disease 
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Excessive angiogenesis 
 Occurs in diseases such as cancer, diabetic blindness, age-related macular degeneration, 
rheumatoid arthritis, psoriasis, and more than 70 other conditions. 
 Occurs when diseased cells and tissue produce abnormal amounts of angiogenic growth 
factors, overwhelming the effects of natural angiogenesis inhibitors. 
 In these conditions, new blood vessels grow and feed diseased tissues; the new vessels are 
abnormal and leaky and can destroy normal tissues. In the case of cancer, the abnormal 
vessels allow tumor cells to escape into the circulation and lodge in other organs (tumor 
metastasis). 
 Antiangiogenic therapies, aimed at halting new blood vessel growth, are used to treat these 
conditions. 
Insufficient angiogenesis 
 Occurs in diseases such as coronary artery disease, stroke, and chronic wounds. 
 In these conditions, blood vessel growth is inadequate, and circulation is not properly 
restored, leading to the risk of tissue death. 
 Insufficient angiogenesis occurs when tissues do not produce adequate amounts of 
angiogenic growth factors. 
 Therapeutic angiogenesis therapies, aimed at stimulating new blood vessel growth with 
growth factors, are being developed to treat these conditions. 
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Table.1 Abnormal angiogenesis/vascular malfunction (Carmeliet and Jain, 2000) 
Organ Processess characterized by abnormal angiogenesis/vascular malfunction 
Blood vessels Atherosclerosis, Haemangioma, Heamangioendothelioma (increased 
vascularisation) 
Vascular malformations (Abnormal remodelling) 
Skin Warts, Pyogenic granulomas, Hair growth, Kaposis sarcoma, scar keloids, 
allergic oedema, neoplasms (Increased vascularisation). 
 Psoriasis (Skin vessels enlarge and become tortuous) (Abnormal remodelling). 
Decubitus or Stasis ulcers, Gastrointestinal ulcers. (Insufficient vascularisation) 
 
Uterus, Ovary, 
Placenta 
Dysfunctional uterine bleeding, Follicular cysts, Ovarian hyperstimulation, 
endometriosis, neoplasms (increased vascularisation). 
Pre-eclampsia (Abnormal remodelling). 
Placental insufficiency (Insufficient vascularisation). 
Peritoneum, 
Pleura 
Respiratory distress, Ascites, Peritoneal sclerosis (dialysis patients), adhesion 
formation (abdominal surgery), metastatic spreading (Increased vascularisation 
and/permeability). 
Heart, Skeletal 
muscle 
Work overload  (increased vascularisation) 
Ischemic heart and limb disease (Insufficient vascularisation). 
Adipose tissue  Obesity (increased vascularisation) 
Bone, Joints Rheumatoid arthritis, Synovitis, Bone and cartilage destruction, 
Osteomyelitis, Pannus growth, Osteophyte formation, Cancer (increased 
vascularisation). 
Aseptic necrosis, impaired healing of fractures (Insufficient vascularisation). 
Liver, Kidney, 
ear, lung and 
other epithelia 
Inflammatory and infectious processes (Hepatitis, Pneumonia, 
Glomerulonephritis), asthma, nasal polyps, transplantation, liver regeneration, 
cancer (increased vascularisation). 
Pulmonary hypertension, diabetes (Abnormal remodelling).     
Pulmonary and systemic hypertension (Insufficient vascularisation). 
Brain, nerves 
and eye 
Retinopathy and prematurity, diabetic retinopathy, choroidal and other 
intraocular disorders, leukomalacia, cancer (increased vascularisation). 
Stroke, Vascular dementia, Alzheimers disease, CADASIL (Insufficient 
vascularisation). 
Endocrine 
organs 
Thyroditis, Thyroid enlargement, Pancreas transplantation (increased 
vascularisation). 
Thyroid pseudocyst (Insufficient vascularisation). 
Haematopoiesis  AIDS, Haematologic malignancies (increased vascularisation). 
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Angiogenesis in diseases 
 
Angiogenesis and diabetic retinopathy 
It is evident that the complication of diabetes is characterized by the formation of new 
vessels inside the retina showing abnormal architecture and permeability. The pathogenesis 
behind visual loss is related with retinal angiogenesis and increased retinal vascular 
permeability. Several mechanisms have been proposed to cause the retinal and vasculature 
cellular damage.  High blood glucose induces hypoxia in retinal tissues, thus leading to the 
production of VEGF-A (vascular endothelial growth factor protein). Hypoxia is a key 
regulator of VEGF induced ocular neovascularisation.  
A persistent increase in blood glucose levels shunts excess glucose into the aldose 
reductase pathway in certain tissues, which converts sugars into alcohol (e.g., glucose into 
sorbitol, galactose to dulcitol). Intramural pericytes of retinal capillaries seem to be affected 
by this increased level of sorbitol, eventually leading to the loss of its primary function (i.e, 
autoregulation of retinal capillaries) (Crawford et al. 2009). 
Angiogenesis and Cancer 
Like tissues of the body, tumors need a blood supply. They get this through new 
blood vessel formation that extends into the tumour (angiogenesis). The nutrients and growth 
factors supplied by these blood vessels allow tumors to grow.  
Before the 1960s, cancer researchers believed that the blood supply reached tumors 
simply because pre-existing blood vessels dilated. But later experiments showed that 
angiogenesis - the growth of the new blood vessels is necessary for cancerous tumors to keep 
growing and spreading. 
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Figure.4 Tumour angiogenesis 
Cancer researchers became interested in angiogenesis factors in 1968, when the first 
hints emerged that tumour might release such substance to foster their own progression. Two 
independent research teams- Melvin Greenblatt of the University of Southern California, 
working with Philipe Shubik of the University of Chicago, and Robert L Eharmann and 
Mogens Knoth of Harvard Medical School showed that burgeoning tumours, release 
unidentified substance that induces existing blood vessels to grow into them. Such 
proliferation promotes tumour growth because it ensures the rich supply of blood loaded with 
oxygen and nutrients. In 1971, Judah Folkman of Harvard proposed that interfering with this 
factor might be a way to kill tumours, by starving them of a blood supply. Folkman later 
posited that blocking the factor would slow cancer‟s spread, a process called metastasis, 
because cancer cells must enter blood vessels to travel to other part of the body.   
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Figure.5 Metastasis 
Tumour Angiogenesis 
Tumour angiogenesis is the proliferation of a network of blood vessels that penetrates 
into cancerous growths, supplying nutrients and oxygen and removing waste products. 
Tumour angiogenesis actually starts with cancerous tumour cells releasing molecules that 
send signals to surrounding normal host tissue. This signal activates certain genes in the host 
tissue that, in turn, make proteins to encourage growth of new blood vessels. For the tumour 
to grow beyond 2-3 mm in size, neovascularization is required. This finding paved the way 
for new anti-angiogenic cancer therapies aimed at disrupting angiogenesis signalling 
pathways (http://cancer.gov/cancertopics/understandingcancer). 
 
Figure.6 Large highly vascularised tumour 
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Activators of Angiogenesis 
Once researchers knew that cancer cells could release molecules to activate the 
process of angiogenesis, the challenge became to find and study these angiogenesis-
stimulating molecules in animal and human tumors. From such studies more than a dozen 
different proteins, as well as several smaller molecules, have been identified as "angiogenic," 
meaning that they are released by tumors as signals for angiogenesis. Many of them are 
growth factors that induce endothelial cells to divide, migrate directionally toward the 
inducing stimulus, and differentiate into tubular structures. Among these molecules, two 
proteins appear to be the most important for sustaining tumor growth: vascular endothelial 
growth factor (VEGF) and basic fibroblast growth factor (bFGF). VEGF and bFGF are 
produced by many kinds of cancer cells and by certain types of normal cells, too. 
(http://cancer.gov/cancertopics/understandingcancer). 
There are at least 20 different known angiogenic growth factors. 
Naturally occurring activators of angiogenesis  
Proteins 
 Acidic fibroblast growth factor 
 Angiogenin 
 Angiopoietin-1 
 Follistatin 
 Basic fibroblast growth factor (bFGF) 
 Epidermal growth factor 
 Granulocyte colony-stimulating factor 
 Hepatocyte growth factor 
 Interleukin 8 
 Leptin 
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 Midkine 
 Placental growth factor 
 Platelet-derived endothelial growth factor 
 Progranulin 
 Proliferin 
 Platelet-derived growth factor-BB 
 Pleiotrophin 
 Scatter factor/ Hepatocyte grouth factor 
 Transforming growth factor alpha 
 Transforming growth factor-beta 
 Tumour necrosis factor alpha 
 Vacular endothelial growth factor (VEGF) 
Small molecules 
 Adenosine 
 1-Butyryl glycerol 
 Nicotinamide 
 Prostaglandins E1 and E2 (Polverini, 1995; Prabhu et al., 2011) 
Angiogenesis signalling Cascade 
Mediators can stimulate angiogenesis directly by interacting with receptors on the 
endothelial cell surface, or indirectly by attracting and activating accessory cells, i.e., 
inflammatory macrophages, and inducing them to produce angiogenic mediators (Polverini 
and Leibovich, 1984). Others, such as copper, may function as co-factors in key interstitial 
enzyme systems or, in the case of plasminogen activator, can activate latent enzymes such as 
transforming growth factor β to reveal its angiogenic (or angiostatic) activity (Roberts and 
Sporn, 1989). Still others play a key role in stabilizing and/or enhancing the function of 
stimulatory molecules normally sequestered in the extracellular matrix surrounding blood 
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vessels, as heparin does, which when bound to basic fibroblast growth factor facilitates its 
interaction with high-affinity receptors on the endothelial cell surface (Folkman and 
Klagsbrun, 1987; Vlodavski et al., 1987). 
VEGF and bFGF are first synthesized inside tumor cells and then secreted into the 
surrounding tissue. When they encounter endothelial cells, they bind to specific proteins, 
called receptors, sitting on the outer surface of the cells. The binding of either VEGF or bFGF 
to its appropriate receptor activates a series of relay proteins that transmits a signal into the 
nucleus of the endothelial cells. The nuclear signal ultimately prompts a group of genes to 
make products needed for new endothelial cell growth. 
 
Figure.7 Angiogenesis signaling cascade 
 
Endothelial Cell Activation 
 
The activation of endothelial cells by VEGF or bFGF sets in motion a series of steps 
toward the creation of new blood vessels. First, the activated endothelial cells produce matrix 
metalloproteinases (MMPs), a special class of degradative enzymes. These enzymes are then 
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released from the endothelial cells into the surrounding tissue. The MMPs break down the 
extracellular matrix support material that fills the spaces between cells which is made of 
proteins and polysaccharides. Breakdown of this matrix permits the migration of endothelial 
cells. As they migrate into the surrounding tissues, activated endothelial cells begin to divide. 
Soon they organize into hollow tubes that evolve gradually into a mature network of blood 
vessels (http://cancer.gov/cancertopics/understandingcancer). 
 
 
Figure.8 Endothelial cell activation 
 
Inhibitors of Angiogenesis 
While the mediators responsible for inducing new capillary growth have been the 
subject of extensive investigation, only recently attention has focused on the mechanisms and 
mediators responsible for the timely down-regulation of angiogenesis (Folkman and 
Klagsbrun, 1987)  
Although many tumors produce angiogenic molecules such as VEGF and bFGF, their 
presence is not enough to begin blood vessel growth. For angiogenesis to begin, these 
activator molecules must overcome a variety of angiogenesis inhibitors that normally restrain 
blood vessel growth. Almost a dozen naturally occurring proteins can inhibit angiogenesis. 
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Among this group of molecules, proteins called angiostatin, endostatin, and thrombospondin 
appear to be especially important. A finely tuned balance between the concentration of 
angiogenesis inhibitors and of activators such as VEGF and bFGF determines whether a 
tumor can induce the growth of new blood vessels. To trigger angiogenesis, the production of 
activators must increase as the production of inhibitors decreases. 
Angiogenesis inhibitors 
There are at least 28 known natural angiogenesis inhibitors found in the body (Polverini, 
1995; Prabhu et al., 2011) 
Proteins 
 Angiostatin 
 Angioarrestin 
 Endostatin 
 Antiangiogenic antithrombin III 
 Cartilage-derived inhibitor (CDI) 
 CD59 complement fragment 
 Fibronectin fragment 
 Gro-beta 
 Heparinases 
 Heparin hexasaccharide fragment 
 Human chorionic gonadotropin (hCG) 
 Interleukin-12 
 Kringle 5 (plasminogen fragment) 
 2-Methoxyestradiol 
 Placental ribonuclease inhibitor 
 Plasminogen activator inhibitor 
 Proliferin-related protein (PRP) 
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 Retinoids 
 Tetrahydrocortisol-S 
 Transforming growth factor-beta (TGF-b) 
 Vasculostatin 
 Vasostatin (Calreticulin fragment) 
 Interferons alpha/ beta/ gamma  
 Interferon inducible protein (IP-10) 
 Platelet factor 4 
 Prolactin 16Kd fragment 
 Thrombospondin 
 Tissue inhibitor of metalloproteinase-1 (TIMP-1) 
 Tissue inhibitor of metalloproteinase-2 (TIMP-2) 
 Tissue inhibitor of metalloproteinase-3 (TIMP-3) 
Angiogenesis inhibitors in treatment of cancer 
Almost two dozen angiogenesis inhibitors are currently being tested in cancer 
patients. These inhibitors fall into several different categories, depending on their mechanism 
of action. Some inhibit endothelial cells directly, while others inhibit the angiogenesis 
signaling cascade or block the ability of endothelial cells to break down the extracellular 
matrix.  
All cancerous tumour release angiogenic growth factor proteins that stimulate blood 
vessels to grow into the tumour, providing it with oxygen and nutrients, Anti-angiogenic 
therapies literally starve the tumour of its blood supply by interfering with this process. New 
classes of cancer treatments that block angiogenesis are now approved and available to treat 
cancers of the colon, kidney, lung, breast and liver, as well as multiple myeloma and bone 
gastrointestinal stromal tumours. Some older drugs have been rediscovered to block angiogenesis 
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as well. These are being used to treatment angiogenesis dependent conditions, such as 
hemangiomas, colon polyps and precancerous skin lesions. 
 
 
Figure.9 Block the ability of endothelial cells to break down the extracellular matrix 
 
 
Figure.10 Molecules that directly inhibit the growth of endothelial cells 
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 Endostatin, the naturally occurring protein known to inhibit tumor growth  
 Combretastatin A4 causes growing endothelial cells to commit suicide (apoptosis).  
 Integrin promote the destruction of proliferating endothelial cells. 
 
Figure.11 Old drug with a new use 
Thalidomide, a sedative used in the 1950s that was subsequently taken off the market 
because it caused birth defects when taken by pregnant women. Although this drug clearly 
would not be suitable for pregnant women, its ability to prevent endothelial cells from 
forming new blood vessels might make it useful in treating non pregnant cancer patients. 
 
Figure.12 Molecules that interfere with steps in the angiogenesis signaling  
cascade 
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 Anti-VEGF antibodies that block the VEGF receptor from binding growth factor. 
 Iterferon- alpha, is a naturally occurring protein that inhibits the production of bFGF 
and VEGF, preventing these growth factors from starting the signaling cascade.  
 Several synthetic drugs capable of interfering with endothelial cell receptors.  
 
 
Figure.13 Drugs That Block Extracellular Matrix Breakdown 
 
MMPs are the enzymes that catalyze the breakdown of the extracellular matrix. 
Because breakdown of the matrix is required before endothelial cells can migrate into 
surrounding tissues and proliferate into new blood vessels, drugs that target MMPs also can 
inhibit angiogenesis. Several synthetic and naturally occurring molecules that inhibit the 
activity of MMPs are currently being tested to see if interfering with this stage of 
angiogenesis will prolong the survival of cancer patients 
(http://cancer.gov/cancertopics/understandingcancer).  
Approved anti-cancer therapies with recognized antiangiogenic properties 
In the U.S., there are currently thirteen approved anti-cancer therapies with 
recognized antiangiogenic properties in oncology. These agents, which interrupt critical cell 
signaling pathways involved in tumor angiogenesis and growth, comprise three primary 
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categories 
1) Monoclonal antibodies directed against specific proangiogenic growth factors and/or their 
receptors.  
2) Small molecule tyrosine kinase inhibitors (TKIs) of multiple proangiogenic growth factor 
receptors. 
3) Inhibitors of mTOR (mammalian target of rapamycin). 
In addition, there are two other approved anti angiogenic agents may indirectly inhibit 
angiogenesis through mechanisms that are not completely understood. Angiogenesis 
inhibitors have also been discovered from natural sources, including tree bark, fungi, shark 
muscle and cartilage, sea coral, green tea and herbs (liquorices, ginseng, cumin, garlic). In 
total, more than 300 angiogenesis inhibitors have been discovered to date. Near about 184 
million patients in World could benefit from some form of anti angiogenic therapy (Prabhu et 
al., 2011).  
Monoclonal Antibody Therapy 
Bevacizumab (Avastin) 
A humanized monoclonal antibody that binds biologically active forms of vascular 
endothelial growth factor (VEGF) and prevents its interaction with VEGF receptors 
(VEGFR-1 and VEGFR-2), thereby inhibiting endothelial cell proliferation and angiogenesis. 
Indications 
 
Metastatic colorectal cancer (mCRC), non-small cell lung cancer (NSCLC), advanced 
breast cancer, glioblastoma, metastatic renal cell cancer (RCC), advanced ovarian cancer.  
 In combination with 5-FU-based chemotherapy as first-line and second-line treatment of 
mCRC. 
 In combination with carboplatin and paclitaxel as first-line treatment of patients with 
unresectable, locally advanced, recurrent or metastatic non-squamous NSCLC. 
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 In combination with paclitaxel as first-line treatment in patients with locally recurrent or 
metastatic breast cancer. 
 Second-line treatment of patients with glioblastoma following temozolomide failure. 
 In combination with interferon-alfa as first-line treatment of RCC. 
 In combination with chemotherapy as first-line treatment in patients with newly 
diagnosed, advanced ovarian cancer. 
Small Molecule Tyrosine Kinase Inhibitors (TKIs) 
Seven TKIs with antiangiogenic activity are currently approved as anticancer therapies 
axitinib (Inlyta), cabozantinib (Cometriq), pazopanib (Votrient), regorafenib (Stivarga), 
sorafenib (Nexavar), sunitinib (Sutent), and vandetanib (Caprelsa). 
Axitinib (Inlyta) 
Oral multikinase inhibitor that targets VEGFR-1, VEGFR -2, VEGFR -3 
Indication: Advanced renal cell carcinoma after failure of one prior systemic therapy. 
Cabozantinib (Cometriq) 
Small molecule tyrosine kinase inhibitor of c-Met and VEGFR2. 
Indication: Progressive, metastatic medullary thyroid cancer. 
Pazopanib (Votrient) 
Small molecule TK inhibitor of VEGF, PDGFR and c-kit 
Indication: Advanced renal cell carcinoma. 
Regorafenib (Stivarga) 
Oral multikinase inhibitor that targets VEGFR-1, -2, -3, TIE2, PDGFR, and FGFR, 
KIT, RET, RAF, BRAF, and BRAFV600E. 
Indication:  Advanced metastatic colorectal cancer (mCRC) that has progressed or has 
recurred after multiple treatments. 
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Sorafenib (Nexavar) 
Small molecule TK inhibitor of VEGFR-1, VEGFR-2, VEGFR-3, PDGFR-ß, and 
Raf-1. 
Indications  
 Treatment of advanced renal cell carcinoma. 
 Treatment of unresectable hepatocellular carcinoma. 
 Treatment of locally recurrent or metastatic, progressive, differentiated thyroid carcinoma 
(DTC) refractory to radioactive iodine. 
Sunitinib (Sutent) 
Small molecule TK inhibitor of VEGFR-1, VEGFR-2, VEGFR-3, PDGFR- ß, and 
RET. 
Indications 
 Advanced renal cell carcinoma, GIST, pancreatic neuroendocrine tumors  
 Treatment of gastrointestinal stromal tumor (GIST) after disease progression on or 
intolerance to imatinib mesylate. 
 Progressive neuroendocrine cancerous tumors located in the pancreas that cannot be 
removed by surgery or that have spread to other parts of the body (metastatic). 
Vandetanib (Caprelsa) 
Small molecule TK inhibitor of VEGFR and EGFR 
Indications 
 Late-stage (metastatic) medullary thyroid cancer in adult patients who are ineligible for 
surgery. 
Inhibitors of mTOR 
Two mTOR inhibitors, temsirolimus (Torisel) and everolimus (Afinitor), are currently 
approved as anti-cancer therapy. 
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Temsirolimus (Torisel) 
A small molecule inhibitor of mTOR (mammalian target of rapamycin), part of the PI3 
kinase/AKT pathway involved in tumor cell proliferation and angiogenesis. 
Indications: Advanced renal cell carcinoma, relapsed or refractory mantle cell 
lymphoma/Non-Hodgkins Lymphoma. 
Everolimus (Afinitor) 
A small molecule inhibitor of mTOR (mammalian target of rapamycin), part of the 
PI3 kinase/AKT pathway involved in tumor cell proliferation and angiogenesis. 
Indications 
 Advanced renal cell carcinoma, pancreatic neuroendocrine tumors, subependymal giant 
cell astrocytoma (SEGA).  
 After failure of treatment with sunitinib or sorafenib. 
 Treatment of progressive neuroendocrine tumors of pancreatic origin (PNET) in patients 
with unresectable, locally advanced, or metastatic disease. 
 Patients with subependymal giant cell astrocytoma (SEGA) who require therapeutic 
intervention but are not candidates for curative surgical resection. 
Other Antiangiogenic Agents 
Interferon alfa (Intron® A and Roferon®) 
An endogenous cytokine with antiangiogenic activity. 
Indications: Hairy Cell Leukemia, Malignant Melanoma, Follicular Lymphoma, AIDS-
Related Kaposi's Sarcoma. 
 
 
Chapter – 1                                                                                                Introduction 
 
Department of Pharmacology                                               The Erode College of Pharmacy  
22 
Lenalidomide (Revlimid®) 
Possesses immunomodulatory, anti-inflammatory, and antiangiogenic properties, 
although the precise mechanisms of action are not fully understood. 
Indications 
 Myelodisplastic Syndrome associated with 5q deletion, Multiple myeloma.  
 Treatment of multiple myeloma in combination with dexamethasone in patients who have 
received at least one prior therapy. 
Thalidomide (Thalomid®) 
Possesses immunomodulatory, anti-inflammatory, and antiangiogenic properties, 
although the precise mechanisms of action are not fully understood. 
Indications 
 Multiple myeloma.  
 Administered in combination with dexamethasone in patients with newly diagnosed 
multiple myeloma. 
rhEndostatin 
Endogenous angiogenesis inhibitor; recombinant protein; blocks VEGF-induced 
tyrosine phosphorylation of KDR-Flk-1 in endothelial cells, and down regulates MMP-2/9. 
Indications: Non-small cell lung cancer (NSCLC) (http://www.angio.org/learn/treatments/).  
Limitations of anti-angiogenesis therapy 
In spite of this undeniable success, current anti-angiogenic therapies have revealed 
some limitations and several unanticipated problems are emerging. 
1. In most tumours (with the exception of renal cell carcinoma), anti-angiogenesis 
treatment requires association with chemotherapy. 
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2. In most patients, addition of anti-angiogenic therapy to current standard therapies 
provides only limited overall survival benefits. 
3. An unexpected problem of antiangiogenesis therapy in cancer is the development of 
resistance. This seems to be common to all currently clinically used anti-angiogenic 
drugs. 
4. There is mounting evidence suggesting that anti-VEGF therapy (or anti-angiogenic 
therapy at large) may paradoxically enhance tumour progression by promoting an 
invasive phenotype that allows the tumour to escape angiogenesis inhibition. 
5. An anti-angiogenic drug would probably stop the normal reproductive cycle in 
women and would be very dangerous to give to pregnant women. 
6. High dosages are necessary to suppress tumor growth.  
7. Other disadvantages of antiangiogenic protein therapy include the need for repeated 
injections and prolonged treatment. 
In a recent investigation, unexpected side effects with combination of bevacizumab 
(anti- VEGF agent) and radiotherapy. Normal tissues toxicity was found to be triggered by 
the combined anti-angiogenic and radiation therapy. 
Diabetic Retinopathy 
Diabetic Retinopathy (DR) is one of the most serious complications of diabetes. Both type-1 
(IDDM) and type-2 diabetes (NIDDM) may lead to blindness due to retinopathy, with type-1 
being more Diabetic retinopathy (DR) is a complication of diabetes mellitus (DM) that 
affects the blood vessels of the retina and leads to blindness. The progression of retinopathy 
is gradual, advancing from mild abnormalities (characterized by increased vascular 
permeability) to moderate and severe non-proliferative DR (characterized by the growth of 
new blood vessels on the retina and posterior surface of the vitreous (Nakazawa 2009). 
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Pathology and etiology of diabetic retinopathy 
Abnormality in functions due to alterations in chemical, molecular biology or retinal 
physiology in the blood retinal barrier leads to early DR. The chemical changes eventually 
induce permeability, surface- adhesive, structural and metabolic changes to cells of the retinal 
capillary wall. This malfunction is the result of the toxicity of high glucose concentrations 
(hyperglycaemia) as well as the toxic effects of by-products from stressed metabolic 
pathways. The affected proteins have structural, catalytic or mediator functions; thus there are 
diverse physical manifestations of early diabetic eye disease. These small symptoms in turn 
give rise to more serious manifestations of DR as the retina attempts to compensate. Auto-
immune or viral destruction of the pancreatic β-cells, leading to insulin deficiency, causes 
Type I diabetes (Forrester and Knott, 1997). Insulin resistance of the cells leads to Type II 
diabetes. The retinal consequences of both these types (type-1 and 2 diabetes) are similar. 
Any variability between the consequences arises out of the different time of diabetes 
diagnosis. Type II diabetics often have sub- clinical disease for many years before receiving 
health care, whereas the symptoms of type I diabetics are acutely manifested in other organs. 
The myriad of consequences of hyperglycemia is the increased viscosity of diabetic blood, 
which is thought to exacerbate the hyperglycemic damage to the endothelial cells and 
basement membrane. The appearance of fenestrae and the lack of tight junctions influence the 
permeability of the vessel walls (Ishibashi and Inomata, 1993). This toxic or bio- chemical 
insult can lead to complete endothelial and pericyte cell loss, so that the capillaries become 
acellular or composed of the basement membrane alone (Stitt et al., 1995). The pericyte 
contractile cells, being only a partial structural component of the capillaries, are believed be 
regulatory in nature. Loss of pericytes cells combined with the loss of smooth muscle mass in 
the larger retinal vessels may increase the haemodynamic pressure, which causes distension 
and ballooning of capillaries also known as Microaneurysms or MA. The damaged 
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endothelium attracts and adheres to the mobile and inflammatory cells of the blood, which 
results in capillary blockage. MAs are the indication of abortive new vessel growth 
attempting to re-canalize or re-perfuse the blocked vessel (Forrester and Knott, 1997). MAs 
represent one of the first clear and easily perceptible changes in microvascular morphology. 
The consequences of pericyte loss, endothelial cell damage and MA formation (potentially 
coupled with impairment of RPE function) are the startingpoint for the development of DR. 
Terms Related To Diabetic Retinopathy: 
i. Microaneurysms: These are the first clinical abnormality to be noticed in the eye. They 
may appear in isolation or in clusters as tiny, dark red spots or looking like tiny haemorrhages 
within the light sensitive retina. Their sizes ranges from 10-100 microns i.e. less than 1/12th 
the diameter of an average optics disc and are circular in shape (The Berries: Diabetic 
Retinopathy,: http://www.theberries.ns.ca/ARchives/2006Winter/diabetic_retinopathy.html), 
at this stage, the disease is not eye threatening. 
ii. Haemorrhages: Occurs in the deeper layers of the retina and are often called „blot‟ 
haemorrhages because of their round shape. 
iii. Hard exudates: These are one of the main characteristics of diabetic retinopathy and can 
vary in size from tiny specks to large patches with clear edges. As well as blood, fluid that is 
rich in fat and protein is contained in the eye and this is what leaks out to form the exudates. 
These can impair vision by preventing light from reaching the retina. 
iv. Soft exudates: These are often called „cotton wool spots‟ and are more often seen in 
advanced retinopathy. 
v. Neovascularisation: This can be described as abnormal growth of blood vessels in areas  
of the eye including the retina and is associated with vision loss. This occurs in response to 
ischemia, or diminished blood flow to ocular tissues. If these abnormal blood vessels grow 
around the pupil, glaucoma can result from the increasing pressure within the eye. These new 
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blood vessels have weaker walls and may break and bleed, or cause scar tissue to grow that 
can pull the retina away from the back of the eye. When the retina is pulled away it is called a 
retinal detachment and if left untreated, a retinal detachment can cause severe vision loss, 
including blindness. Leaking blood can cloud the vitreous (the clear, jelly-like substance that 
fills the eye) and block the light passing through the pupil to the retina, causing blurred and 
distorted images. In more advanced proliferate retinopathy; diabetic fibrous or scar tissue can 
form on the retina (Vallabha et al., 2004). 
Diabetic retinopathy has four stages or severity levels which are summarized in Table1  
1. Mild Nonproliferative Diabetic Retinopathy (NPDR). At this earliest stage, small areas 
of balloon-like bulges called microaneurysms may protrude from the walls of the retina‟s tiny 
blood vessels.  
2. Moderate NPDR. As the disease progresses, some blood vessels that nourish the retina are 
blocked 
3. Severe NPDR. Many more blood vessels are blocked, depriving several areas of the retina 
with their blood supply.  
4. Proliferative Diabetic Retinopathy (PDR). At this advanced stage, the retina sends 
signals for nourishment, triggering the growth of new blood vessels that are abnormal and 
fragile. The new blood vessels grow along the retina and toward the vitreous, the gel-like 
fluid that fills the inside of the eye. They may leak blood into the vitreous, causing severe 
vision loss and blindness.  
The classic retinal microvascular signs of nonproliferative diabetic retinopathy are 
microaneurysms, hemorrhages, hard exudates (lipid deposits), cotton wool spots 
(accumulations of axoplasmic debris within adjacent bundles of ganglion cell axons), venous 
dilation and beading, and intraretinal microvascular abnormalities 
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Table 2. International Clinical Diabetic Retinopathy Disease Severity Scale 
 
 
 
 Figure. 14  Non-proliferative diabetic retinopathy. 
Non-proliferative diabetic retinopathy. Cardinal signs are retinal microaneurysms, 
hemorrhages, and hard exudates (A and B); and intraretinal microvascular 
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abnormalities (C, arrow); venous beading (D, arrow); and venous loop formation (E, 
arrow). 
 
 
 
Fig: 15  Proliferative diabetic retinopathy. 
Proliferative diabetic retinopathy. Neovascularization, a hallmark of proliferative 
diabetic retinopathy (A, arrows), which can be identified on fluorescein retinal 
angiogram (B, arrows); resolution of retinopathy with panretinal photocoagulation 
(C); progression of retinopathy without treatment to fibroproliferative disease  (D) 
(Cheung et al. 2010). 
Causes of Vision Loss and Risk Factors in diabetic retinopathy 
Blood vessels damaged from diabetic retinopathy can cause vision loss in two ways   
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1. Fluid can leak into the macula, the area of the retina that is responsible for sharp, clear, 
central vision and allows us to see colors and fine detail. The fluid makes the macula swell, 
blurring vision. This condition is called macular edema (Ferris and Patz 1984). It can occur at 
any stage of diabetic retinopathy, although it is more likely to occur as the disease progresses. 
About half of the people with proliferative diabetic retinopathy also have macular edema. 
2. Fragile, abnormal blood vessels can develop and leak blood into the center of the eye, 
blocking vision. This is proliferative diabetic retinopathy and is the fourth and most advanced 
stage of the disease. Other complications include detachment of the retina due to scar tissue 
formation and the development of glaucoma, an eye disease causing progressive damage to 
the optic nerve. In cases of proliferative diabetic retinopathy, the cause of this nerve damage 
is extremely high pressure in the eye. If left untreated, proliferative diabetic retinopathy can 
cause severe vision loss and even blindness. 
All people with diabetes–both type 1 and type 2–are at risk for the development of 
diabetic retinopathy. The longer the patients have diabetes, the more likely they will develop 
diabetic retinopathy. Between 40 to 45 percent of Americans diagnosed with diabetes have 
some stage of diabetic retinopathy (http://www.nei.nih.gov/health/diabetic/retinopathy; 
Kempen et al. 2004). People with other medical conditions such as high blood pressure and 
high cholesterol are at greater risk
 
(http://www.aoa.org/patients-and-public/eye-and-
visionproblems/ glossary-of-eye-and-vision-conditions/diabetic-retinopathy?sso=y). Pregnant 
women face a higher risk for developing diabetes and diabetic retinopathy
 
(Best and 
Chakravarthy 1997). If gestational diabetes develops, the patients are at much higher risk of 
developing diabetes as they age. Everyone with diabetes is recommended to get a 
comprehensive dilated eye examination at least once a year, since macula edema and 
proliferative diabetic retinopathy can develop without symptoms, such that patients are at 
high risk for vision loss. 
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Current Treatments of Diabetic Retinopathy  
Treatment of diabetic retinopathy depends on the stage of the disease. During the first three 
stages of diabetic retinopathy, no treatment is needed, unless macular edema occurs.  
Laser Surgery  
If the disease advances, leakage of fluid from blood vessels can lead to macular edema, which is 
treated with laser surgery. This procedure is called focal laser treatment (photocoagulation) 
(http://www.nei.nih.gov/health/diabetic/retinopathy; http://www.aoa.org/patients-and-
public/eye-and-visionproblems/glossary-of-eye-and-vision-conditions/diabetic 
retinopathy?sso=y). Up to several hundred small laser burns are created in areas of the retina 
with abnormal blood vessels to try to seal the leaks and reduce the amount of fluid in the retina. A 
patient may need focal laser surgery more than once to control the leaking fluid. When blood 
vessel growth is more widespread throughout the retina, as in proliferative diabetic retinopathy, a 
laser surgery called scatter laser treatment is needed 
(http://www.nei.nih.gov/health/diabetic/retinopathy; Neubauer and Ulbig 2007) 1,000 to 
2,000 scattered laser burns are created in the areas of the retina away from the macula, causing 
the abnormal blood vessels to shrink and disappear. Because a high number of laser burns are 
necessary, two or more sessions usually are required to complete treatment. With this procedure, 
peripheral vision may be partially lost in order to preserve central vision. Scatter laser treatment 
may slightly reduce color vision and night vision.  
Vitrectomy  
In more advanced cases such as severe bleeding, a surgical procedure called a vitrectomy 
may be needed to restore sight by removing significant amount of blood from the center of 
the eye (vitreous gel) (http://www.nei.nih.gov/health/diabetic/retinopathy; Smiddy and Flynn 
1999). Retinal detachment, defined as separation of the light-receiving lining in the back of 
the eye, resulting from diabetic retinopathy, may also require surgical repair 
(http://www.aoa.org/patients-and-public/eye-and-visionproblems/glossary-of-eye-and-vision-
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conditions/diabetic-retinopathy?sso=y). A vitrectomy is performed under either local or 
general anesthesia. A doctor makes a tiny incision in the eye of a patient. Next, a small 
instrument is used to remove the vitreous gel that is clouded with blood and replace it with a 
salt solution to maintain the normal shape and health of the eye. Since the vitreous gel is 
mostly water, the patient will notice no change between the salt solution and the original 
vitreous gel. The patient‟s eye will be red and sensitive. The patient will need to wear an eye 
patch for a few days or weeks to protect the eye, and also need to use medicated eye drops to 
protect against infection.  
Anti‐VEGF Therapy  
Anti-VEGF therapies are important in the treatment of diabetic retinopathy. They can involve 
monoclonal antibodies such as bevacizumab, antibody derivatives such as ranibizumab, or 
orally-available small molecules that inhibit the tyrosine kinases stimulated by VEGF. Both 
antibody-based compounds are commercialized. The efficacy of treatment with the anti-
VEGF agents ranibizumab and bevacizumab indicates that VEGF contributes to the 
pathogenesis of diabetic macular edema and reflects successful translational research. 
Natural resources for the exploration of anti-angiogenic substances 
 For over 40 years, natural products have served us well in combating cancer. The 
main sources of these successful compounds are microbes and plants from the terrestrial and 
marine environments. 
A variety of antiangiogenic substances have also been isolated from natural sources. 
Fumagillin, produced by Aspergillus fumigatis, was one of the first agents found to act as an 
anti-angiogenesis compound. Other antiangiogenic substances from natural sources are shark 
cartilage, curcumin, the omega-3 and omega-6 fatty acids, green tea, licorice, quercetin, 
squalamine, and vitamin D3 (Marwick, 2001). Apart from shark cartilage, some marine 
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natural compounds from sponges and sponge-associated bacteria have also been reported to 
posses antiangiogenic potential (Marwick, 2001). 
 
 
Emerging role of medicinal plants in angiogenesis inhibition 
 
Plants have a long history of use in the treatment of cancer. Three quarters of anti-
tumour compounds used in medicine are natural products or related to them. Of the 140 anti-
cancer agents approved since 1940 and available for use, over 60% can be traced to a natural 
product. Of the 126 small molecules among them, 67% are natural in origin (Cragg and 
Newman, 2005). In 2000, 57% of all drugs in clinical trials for cancer were either natural 
products or their derivatives. From 1981 to 2002, natural products were the basis of 74% of 
all new chemical entities for cancer. Of 155 FDA-approved small molecule anti-cancer drugs, 
47% were natural products. 
 Since angiogenesis plays a prominent role in tumour growth and metastasis, inhibition 
of angiogenesis is considered as an important strategy for cancer therapy. Studies on a global 
scale now focus to identify and develop anti-angiogenic factors to prevent growth and 
metastasis of tumour. Thus identification of a anti-angiogenic agent from natural sources that 
effectively act at various steps of angiogenic cascade could be of great clinical significance. 
Angiogenesis inhibition from plant sources are matter of great interest in recent times. 
Accordingly, numerous bioactive plant-derived compounds have been tested for their 
antiangiogenic potential. Systematic review shows that, many Indian Medicinal plants 
possess anti –VEGF activity.   
 With more than $4 billion invested in the research and development of 
antiangiogenic medicines, something has to come of this massively-financed area of research. 
The natural sources might have an important role in development of more potent, less toxic 
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and cheapest antiangiogenic agents. Anti-angiogenic agent from natural sources may 
complement the efficacy of chemotherapy and radiotherapy without much toxicity. 
 
 
Table.3 List of Indian medicinal plants with anti-VEGF activity (Kumar et al. 2013) 
Latin name  
 
Family   
 
 
 
 
 
 
 
 
Tinospora cordifolia  
 
Menispermaceae  
Tinospora cordifolia  
 
Menispermaceae  
Ocimum sanctum  
 
Lamiacea  
Azadirachta indica  
 
Meliaceae  
Azadirachta indica  
 
Meliaceae  
Calotropis procera  
 
Apocynaceae  
Withania somnifera  
 
Solanaceae  
Withania somnifera  
 
Solanaceae  
Curcuma longa  
 
Zingiberaceae  
Curcuma longa  
 
Zingiberaceae  
Commiphora mukul  
 
Burseraceae  
Piper longum  
 
Piperaceae  
Andrographis paniculata  
 
Acanthaceae  
Peganum harmala  
 
Nitrariaceae  
Vernonia cinerea  Asteraceae  
Boswellia serrata  Burseraceae  
 
METHODS FOR ASSAYING ANGIOGENESIS IN-VITRO AND IN-VIVO 
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One of the most important technical challenges in study of angiogenesis is selection 
of the appropriate assay. There are increasing number of angiogenesis assays being described 
both in-vitro and in- vivo (Staton et al., 2004).  
 
 
In-vitro assay of angiogenesis 
1. Endothelial cells in-vitro 
2. Assays for endothelial cell migration 
3. Differentiation assays 
4. Organ culture assay 
In-vivo assay of angiogenesis 
1. Implantation of sponges and polymers 
2. Chick chorioallantoic membrane assay 
3. Corneal angiogenesis assay 
4. Dorsal air sac model 
5. Chamber assays 
6. Tumour models 
7. Angiomouse 
8. Zebrafish assay 
Chick chorioallantoic membrane assay 
The Chick chorioallantoic membrane (CAM) assay is probably the most widely used 
in-vivo assay for studying angiogenesis (Nguyen et al., 1994).The test substance is prepared 
either in slow-release polymer pellets, absorbed by gelatin sponges, or air-dried onto plastic 
discs; these are then implanted onto the CAM through a window cut carefully in the eggshell. 
The lack a mature, immune system in 7-8 day old chick embryos allows for the study of 
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tumour induced angiogenesis (Folkman, 1975). The angiogenic effects can be measured by 
counting the number of blood vessels in a given area using a stereomicroscope.  
The CAM assay is relatively simple and inexpensive in-vivo assay suitable for large 
scale screening.  
Chorioallantoic membrane 
In the chick embryo, the chorioallantois is formed between days 4 and 5 of 
development, when the outer mesodermal layer of the allantois fuses with the mesodermal 
lining of the chorion, and a network of blood vessels is gradually formed between the two 
layers. The central portion of the CAM is fully developed by day 8 to 10 at which time it 
becomes capable of sustaining tissue grafts, while the outskirts of the CAM are still 
developing and expanding until the CAM fully envelopes the embryo at day 12 of incubation. 
Histologically, the CAM consists of three germ layers, that is, ectoderm, mesoderm, and 
endoderm. The ectoderm faces the shell membrane and is underlined by the respiratory 
capillary plexus, which starts to form between days 5 and 6 of embryonic development by 
both angiogenesis and vasculogenesis (Melkonian et al., 2002). This capillary plexus is very 
dense and appears as a honeycomb network of tiny capillaries originating from terminal 
capillaries. The mesoderm of the chorioallantois is a collagen-rich embryonic connective 
tissue transversed by blood vessels belonging to the arteriolar and venous systems. The 
mesoderm is underlined with a thin endoderm layer, which separates the CAM from the 
allantoic cavity. 
Until day 11 or 12 of chick embryo development, the blood vessel system of the CAM 
is highly angiogenic, that is, undergoing maturation through a constant generation of new 
blood vessels as well as establishment of new blood vessel anastomoses. Therefore, between 
day 8 and day 10, the developing CAM vasculature is ready to sprout in response to 
additional proangiogenic stimuli and, in turn, is very responsive to antiangiogenic factors. 
This feature renders the chick embryo CAM models well suited for experimental validation 
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of pro and anti-angiogenic compounds. In addition, the chick embryo is naturally 
immunoincompetent until embryonic day 17, thus allowing for grafting of cells of different 
species origin, such as human tumor cells, and therefore providing a useful tool for analysis 
of the proangiogenic potential of test cells. 
 
 
 
Figure.16 Development of Chorioallantoic membrane 
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REVIEW OF LITERATURE 
PLANT PROFILE 
 
 
 
 
 
 
 
             Punica granatum tree                                                     Root part of Punica granatum 
 
 
 
 
 
                                                    Dried roots of Punica granatum 
 
Fig:17 Tree, root part and dried roots of punica granatum 
                                                                                                          
 
Taxonomical classification 
Kingdom  - Plantae plant 
Subkingdom  - Trachebionta –vascular plants 
Superdivision  - Spermatophyta-seed plants 
Division  - Magnoliphyta –flowering plants 
Class   - Magnolipsida- dicotyledons 
Subclass  - Rosidae 
Order   - Ryrtales 
Family   - Punicaceae pomegranate family 
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Genus   - Punica L. Pomegranate 
Species  - Punica granatum L. pomegranate 
Table 4: VERNACULAR NAMES 
arabic 
Gulnar Philipin Grande 
assames 
Dalim punjabi Da,danu 
Bengali 
Dalimgachh Russian Granatik 
english 
Pomegranate Sanskrit Bijapura 
Hindi 
Anar Spanish Grando 
Italian 
Melogrante Swedish Granated 
kannada 
Daadima Tamil Madulai 
malayalam 
Urumampalam Telugu Karakamu 
Marathi 
Dalimba Tibetian Se bru 
persian 
Darakhte-gulnar urdu Anarmitha 
 
Description 
The species is globally distributed in South Europe, Pakistan, India, West Asia. 
Within India, it is wild in the Western Himalayas between on altitude range of 900-1800 m., 
and is cultivated throughout the country for its fruits. 
Chapter – II                                                                                              Reivew of Literature 
 
Department of Pharmacology                                               The Erode College of Pharmacy  
39 
A shrub or small tree growing 6 to 10 m (20 to 33 ft) high, the pomegranate has 
multiple spiny branches and is extremely long-lived, with some specimens in France 
surviving for 200 years.  
Leaves 
Punica granatum leaves are opposite or sub-opposite glossy, narrow oblong, entire, 3-
7 cm (1.2-2.8 inch) long and 2 cm broad. The flowers are bright red and 3cm in diameter, 
with three to seven petals. Some varieties are grown for the flowers alone. 
Blossoms  
                  Produced in summer where rainfall is minimal during late summer. 
Flower  
         Colour: bright red with 5 to 8 crumpled petals which ersists in the fruit. 
         Size    : 3 cm in diameter. 
Fruit 
The edible fruit is a berry, intermediate in size between a lemon and a grapefruit, 5-12 
cm (2.0-4.7 in) in diameter with a rounded shape and thick, reddish skin. The number of 
seeds in a pomegranate can vary from 200 to about 1400. Each seed has a surrounding water 
laden pulp- the edible sarcotesta that forms from the seed coat- ranging in color from white to 
deep red or purple. The seeds are exarillate i.e. unlike some other species in the order, 
myrtales, no aril is present. The sarcotesta of pomegranate seeds consists of epidermis cells 
derived from the integument. The seeds are embedded in a white, spongy, astringent 
membrane.  
Pomegranate juice, obtained by compressing the seeds, causes a deep red stain which 
is difficult to remove. The pigmentation of pomegranate juice results from the presence of 
anthocyanins and ellagitannins (Dipak et al. 2012).  
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Traditional uses 
Heart problem 
Frequent intake of pomegranate juice can maintain good folw of the blood in the 
body. Along with this, it decreases the risk of heart attack and heart strokes.  
Stomach disorder  
Pomegranate peel, bark and leaves are used to calm the stomach disorder or diarrhea 
triggered due to any kind of digestive problems. Drinking tea made from the leaves of this 
fruit helps in curing digestive problems. Pomegranate juice is also used for handling 
problems of dysentery and cholera. 
Dental care 
The best benefit of pomegranate is that its juice, along with its antibacterial and anti 
viral properties, helps to reduce the effects of dental plaque. 
Cancer 
Pomegranate consists of advanced level of antioxidants called flavonoids. These 
flavonoids are thought to be effective in counteracting various cancer radicals. The 
individuals that face high risk of prostate and breast cancer should start drinking the juice of 
this fruit, as this will help them to reduce further risk of developing cancer. Regular 
consumption of pomegranates can reduce the PSA levels in the body and helps to fight the 
existing cancer cells in the body. 
Osteoarthritis  
Pomegranate minimizes the illness triggered in various forms like atherosclerosis and 
osteoarthritis. The loss that is triggered due to the thickening and solidifying of the arterial 
walls and in cartilage and joints can be cured by consuming this fruit. Also, pomegranate is 
capable of preventing the creation of minerals that are liable for breaking down the 
connective tissues. 
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Diabetic anemia  
Consuming of pomegranate fruit juice by a diabetic patient can prevent coronary 
illness. Along with this, there is a slowdown in solidifying of the bloodstream, which can fuel 
non-occurrence of various heart disease. 
Anemia 
Healthy blood flow can be maintained in the body by consuming this fruit in any 
form. Pomegranate seed extract supplies iron to blood and thus help to decrease the anemic 
symptoms including fatigue,wooziness and weakness and hear loss. (Bhowmik et al. 2013) 
OTHER ADVANTAGEOUS FORMS OF 
Pomegranate 
With the passage of time, more and more people have started acknowledging the 
importanceofconsumingpomegranates.Thereareotheradvantagetoo,like pomegranate reduces 
the likelihood of having premature infants and it is also beneficial for the expected mothers to 
avoid having low weight infants during birth.  
Pomegranate seed extract also reduces the likelihood of creating Alzheimer‟s disease 
among the elderly. It helps controlling aging issues like wrinkles and thus, facilitates youthful 
and glowing skin. Other than this, it allows a woman to overcome from her depression 
interval , especially from the menopause period.  
The pomegranate fruit juice is also known to be very helpful in treating issues of 
erectile dysfunctions. It is a good natural aphrodisiac and improves sperm count and semen 
quality. The astringent features of the flower juice, rind and tree bark are considered valuable 
for a wide range of purposes, such as stopping nose bleeds and gum bleeds, toning skin (after 
mixing with mustard oil) firming-up sagging breasts and treating hemorrhoid. Pomegranate 
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seed (of specific fruits trains) is also used as eye drops as it is believed to slow the 
development of cataracts.   Pomegranate is used as a gargle for a sore throat,and it is applied 
to the epidermis to cure hemorrhoid flare-ups. It cleanses and clarifies oral cavity, throat, 
esophagus stomach and chest. 
Health benefits of pomegranate 
 Free radicals 
Pomegranates are a rich source of anti oxidants that helps to protect our body's cells 
from free radicals, which cause premature aging. Free radicals are formed due to exposure to 
the sun and harmful toxins from the environment. 
 Pomegranate is natural blood thinners: 
Prevents  blood clots in the heart and arteries, also urinary retention. The seeds 
prevent your blood platelets from coagulating and forming clots. 
Arthritis prevention: 
Pomegranate can reduce the damage on the cartilage for those hit with arthritis. This 
fruit has the ability to lessen the inflammation and fights the enzymes that destroy the 
cartilage. 
Help in erectile dysfunction: 
Pomegranate juice can improve erectile dysfunction only moderately.  
Prostrate cancer and heart diseases: 
Two separate studies claim that pomegranate juice helps fight prostate cancer. In one 
lab experiment, the juices "slowed the growth of the cultured cancer cells and promoted cell 
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death". In the second experiment, pomegranate juice improved the condition of the blood, 
hence improving the health of individuals down with cardiovascular diseases. 
Prevention of atherosclerosis: 
Pomegranates prevent the hardening of the artery walls with excess fat, leaving your 
arteries fat free and pumping with antioxidants. 
Medicinal Properties of Pomegranates 
The word “Pomegranate" (Punica granatum) comes from the Latin for "fruit of many 
seeds." 
In folk medicine, the fruit's astringent properties have been used to treat various 
ailments (cuts,sore throats, tapeworms, dysentery, and gum disease). Pomegranate juice is 
marketed in the United States as a major source of anti oxidant nutrients that protect against 
heart disease and other ailments.  
Recent research has focused on its potential use as a treatment for cardio vascular 
disease, diabetes, and various forms of cancer. The author examines those properties of the 
pomegranate, as well as its history and nutritional and chemical makeup.  
Pomegranates are believed to be native to the areas from eastern Iran through northern 
India, says the author. More than adozen cultivars of the fruit ("Wonderful" being the leading 
commercial cultivar in the United States) have been grown commercially in California's San 
Joaquin Valley since its introduction by Spanish settlers in the late 18thcentury.  
Pomegranates are a good source of vitamin C, providing between 1020% of there 
commended daily allowance according to onesource1 and up to 40% according to another. 
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The potent antioxidant properties of the fruit have been attributed to its high content of 
soluble polyphenols.  
When tested in vitro on normal and colon-cancer cell lines, the juice was found to 
have superior antioxidant, anti proliferative, and pro apoptotic effects compared with single 
purified active ingredients, probably the result of synergistic actions among the fruit's 
multiple compounds. Studies have shown that the antioxidant activity of the pomegranate 
flowers yielded activity two to three times the antioxidant potency of tea or red wine.  
The author notes research suggesting that pomegranate juice maybe cardio protective, 
reducing risk factors (such as cholesterol accumulation, foam-cell formation in macrophages, 
and oxidized low-density lipoprotein [LDL]) without affecting native LDL. Cited by the 
author is an Israeli study in which 10patients with carotid artery stenosis (advanced plaque 
build-up in the arteries) drank pomegranate juice and experienced reduced blood pressure, 
LDL oxidation, and progression of carotid lesions at 1-year and 3-year study intervals. In a 
randomized, double-blinded, placebo-controlled study at the Preventive Medicine Research 
Institute in Sausalito, CA, pomegranate juice drinkers with coronary artery disease had a 17% 
improvement in blood flow compared with an 18% worsening in the control group.  
The study team concluded that the antioxidants in the juice may help prevent the 
formation of fatty deposits on artery walls. In studies of the fruit's anticancer effects, 
pomegranate fruit extract (PFE) has been found to be chemo preventive in mouse mammary 
organ culture and in human breast cancer cells in vitro. In another study cited by the author, 
researchers at the University of Wisconsin in Madison found that PFE significantly reduced 
serum prostate specific antigen levels and inhibited proliferation of aggressive human 
prostate cancer cells in athymic mice.  
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Pomegranate extracts have exerted anti proliferative, anti estrogenic, and pro 
apoptotic actions on leukemia cells as well as breast- and prostate-cancer cells. Results of 
studies with diabetic patients have shown that supplementing the diet with pomegranate juice 
had beneficial antioxidant effects on macrophages, implying that it could reduce the 
development of atherosclerosis.  
Australian researchers found that pomegranate flower extract reduced factors 
(hyperglycemia, hyperlipidemia, and a fatty heart) that can result in increased cardiac 
impairing fibrosis in patients with type 2 diabetes. Other studies have shown the benefits of 
pomegranate in promoting neurologic health ,maintaining joint integrity and function, 
exhibiting estrogenic properties, blocking herpes simplex virus replication and adsorption, 
enhancing immune function, treating periodontal disease, enhancing the activity of antibiotics 
used to treat methicillin -resistant and methicillin sensitive Staphylococcus aureus infections, 
and preventing smooth muscle dysfunction and fibrosis in erectile dysfunction. The author 
also mentions other uses of the fruit.  
In Ayurvedic medicine, the astringent properties of pomegranates are linked with 
bone and cartilage build-up; in the cosmetic arena, fruit-peel extract has been shown to 
stimulate a type of pro collagen synthesis and inhibit a dermal degeneration process. The 
antioxidant, immune-boosting, and ante carcinogenic properties of the pomegranate, says the 
author, offers multiple potential medical applications (Bhowmik et al. 2013). 
Medicinal Benefits 
Pomegranate is a poly-vitamin, a unique fruit plant producing a wide spectrum of 
biologically active substances especially important in our present-day polluted environment. 
It helps in preventing the harmful effects of radioactive substances by producing biologically 
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active substances. Russians, after the deadly Chernobyl tragedy, used pomegranates to reduce 
the effect of radioactive substances.  
In order to maintain the health and energy levels of astronomers, submariners and coal 
miners, they often consume pomegranate juice regularly. Pomegranate is loaded with tannins, 
anthocyanins, polyphenolic sand antioxidant vitamins, A, E and C, all of which have a health 
effect on the body. These elements work together to benefit the arteries, plus it keeps the 
cardiovascular system healthy which is the chief health benefit of Pomegranate.  
It has also been found to increase levels of nitric oxide, which improve blood flow to 
the heart, reduce arterial plaque, reduce systolic blood pressure and help in curing erectile 
dysfunction. Other benefits include preventing premature aging, stroke, arthritis, Alzheimer's 
and even cancer. The juice of the red pomegranate has received attention for its rich flavor 
and health boosting properties. If you cut a pomegranate open, you will see the many tiny 
pomegranate" arils" or seeds that are contained inside.  
The juice comes from the crushed seeds. Pomegranate juice has been shown to 
contain more antioxidants than most fruit juices, red wine or green tea, according to Health 
Castle. 
Antimicrobial Properties 
Drinking pomegranate juice has been shown to have antimicrobial properties against 
harm full bacteria that can exist in the stomach, such aseschericia Coli (e.Coli) or Bacillus 
subtilis, both of which can cause painful infections and serious stomach conditions. 
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Fighting Cancer 
Pomegranate contains a number of beneficial antioxidants, including polyphenols, 
tannins and anthocyanins. Antioxidants protect against free radicals, which are by-products of 
cell oxidization. Free radicals are associated with causing a number of health problems, 
including breast, prostate and lung cancers.  
Drinking pomegranate juice has been shown to shrink prostate tumors in mice, and 
this could be due to the fact that antioxidants contained within pomegranate juice help to 
fight against free radical damage. This also boosts immunity, which helps to lower the risk of 
cancer incidence. 
Essential Vitamins and Minerals 
Pomegranate juice is high in a number of vitamins and minerals, including 40 percent 
of the recommended daily allowance of Vitamin C perserving. Other essential vitamins and 
minerals include Vitamins A and E and folic acid. Meeting daily health requirements helps to 
enhance health and boost immunity. 
Protects against Arthritis 
Pomegranate juice contains an enzyme inhibitor that prevents enzymes from 
damaging cartilage in the body. This benefit helps to prevent the onset of or even symptoms 
associated with osteoarthritis. 
Blood Thinner 
Drinking pomegranate juice has been shown to act as a natural blood thinner. This 
helps to increase the flow of blood to the heart while also reducing arterial plaque. While 
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pomegranate juice alone would not act as a strong enough blood thinner on its own in those 
with heart disease, the juice can still have a beneficial effect on the heart. Pomegranate is a 
tree. Various parts of the tree and fruit are used to make medicine.  
Pomegranate is used for many conditions, but so far, there isn‟t enough scientific 
evidence to rate pomegranate as effective for any of them. We do know, though, that 
pomegranate does not seem to be effective for reducing the symptoms of chronic obstructive 
(COPD) or improving breathing in people with this condition.  
Pomegranate is used for conditions of the heart and blood vessels, including high 
blood pressure, congestive heart failure (CHF), heart attack, “hardening of the arteries” 
(atherosclerosis), and high cholesterol. It is also used for conditions of the digestive tract, 
including diarrhea, dysentery, and tapeworm and other intestinal parasites .Some people use 
pomegranate for flu, swelling of the lining of the mouth (stomatitis), gum disease, erectile 
dysfunction (ED), diabetes and a complication called acidosis, bleeding, and HIV disease. It 
is also used for preventing prostate cancer, obesity, and weight loss.  
Some women use pomegranate to cause an abortion. Pomegranate is used as a gargle 
for sore throat , and it is applied to the skin to treat hemorrhoids. Pomegranate (Punica  
granatum) is unique among plants. The only other plant that is closely related is a small tree 
that grows only on an island in Yemen.  
Pomegranate has been used for thousands of years to treat a wide variety of diseases. 
It is in Greek, Hebrew, Buddhist ,Islamic, and Christian mythology and writings. It is 
described in records dating from around 1500BC as a treatment for tapeworm and other 
parasites (Bhowmik et al. 2013).. 
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Medicinal Uses of Punica granatum L 
(Pomegranate) 
Pomegranate fruit juice is known as a delicacy and is made into excellent sherbet with 
the addition of water, sugar and taken internally, and some people use it in preparing ice-
creams, jellies and marmalades.  
Such juice of pomegranate fruits possesses diuretic, cooling effect, glucose, fructose, 
tannins, oxalic acid, and reduces thirst in cases of fevers, supplies the required minerals and 
helps the liver to preserve vitamin A. from the food, increases the body's resistance to T. B 
infection, and acts as a tonic for heart and kidney.  
According to Indian Herbal System, all parts of pomegranate including roots, leaves, 
flowers, rind, seeds and the reddish brown bark are used medicinally. Pomegranate bark and 
root contains several alkaloids including iso pelletierine that fights against tapeworms.  
Pomegranate bark, leaves, immature fruit and fruit rind extracts is given to combat 
diarrhea, dysentery and hemorrhages, whilst powdered flower buds acts as a remedy for nose 
bleeding. For bleeding piles; the bark decoction is very effective, and if combined with 
Holarrhena‟s bark with a sip of honey it treats blood motions. 
 For threatened abortion; pomegranate leaves, sandal wood powder, curd and a sip of 
honey are useful .For gum bleeding and bleeding of the teeth; the fruit rind powder mixed 
with black pepper, common salt, and applied. Such preparation whitens teeth, strengthens 
gum and said to prevent pyorrhea. For urinary calculus; a teaspoonful of ground seeds along 
with a cup of gram soup taken internally For diarrhea, dysentery, nose bleeding, prolapsed 
rectum, leucorrhea, etc.; powdered dried rind with fenugreek decoction and a sip of honey are 
beneficial.  
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The flower bud can also be snuffed in case nose bleeding. For conjunctivitis; a paste 
of the leaves is applied on the red part of the eye. This is also beneficial in healing scabies, 
eczema, itchiness and ringworm. It has immuno- stimulatory, anti-oxidant ,anti-inflammatory 
anti-diabetic and anticancer. It is widely used in treating certain types of cancer including 
gleukemia, breast, prostate and colon cancer, dysentery, diarrhea, excessive bleeding, 
intestinal worms and parasites. 
Recent Research 
New therapies for preventing cancer may be on their way as scientists have identified 
components in pomegranate juice that inhibit the movement of cancer cells. Researchers at 
the University of California have found that these components also weaken cancer cells 
attraction to a chemical signal that promotes the metastasis of prostate cancer to the bone. 
 The research could lead to new therapies for preventing cancer metastasis .Manuela 
Martins-Green applied pomegranate juice on aboratory-cultured prostate cancer cells that 
were resistant to testosterone. The researchers found that the pomegranate juice treated 
tumour cells that had not died with the treatment showed increased cell adhesion and 
decreased cell migration (Bhowmik et al. 2013). 
Chemical constituents 
Alkaloids 
 It was indicated that alkaloids was present at the rate of 3% in the roots. It was also 
indicated that  
 Pseudopelletierine 
 Pelletierine 
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 Isopelletierine 
 Methylpelletierine 1- pelletierine 
 dl-pelletierine 
 Methyl isopelletierines, were found in composition of the root, 
body and branch rinds of Punica granatum. 
Tannins 
It was stated that punicacortein A B C D in the structure of hydrolysable c-glycoside, 
which is a new ellagitannin, as well as punigluconin which contains one gluconic acid and 
also casuariline and casuarine were present in the fresh body roots of Punica granatum. 
Ellagitannins including punicalin and punicalagin. 
Triterpenic acids 
Presence of ursolic acid one of the compounds in triterpenic structure was determined 
in different sections of the pomegranate plant. 
Biochemical constituents: 
             Three current research seems to indicate the most therapeutically beneficial 
pomegranate constituents are ellagic acid ellagitannins (including punicalagins), punicic acid, 
flavonoids, anthocyanindins, anthocyanins and estrogenic flavonols and flavones 
(Mohammed and Kashani 2012). 
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Scientific claims of Punica granatum L. 
 Jayakumar et al. 2012   evaluated the anticancer activity of Punica granatum rind 
extract against human lung cancer cell line A549. Punica granatum extract produced 
a dose dependent inhibitory effect on cell growth (IC50-80µg/ml) and significantly 
inhibited the growth of A549 cells. 
 Sajjad et al. 2015   evaluated the antitumor potential of Punica granatum peel 
extract. The antitumor activity was examined by using Agrobacterium tumefaciens At 
10 strain and potato disc tumor assay technique and assessment were established on 
the basis of tumor inhibition of several concentration of extract (10ppm, 
100pm,1000pm). Results discovered that different concentration of Punica granatum 
peel extract showed different % of inhibition. Increase in percentage inhibition of 
tumor were observed with increase of peel extract concentration. At 1000ppm, crude 
ethanolic extract (CEE) showed maximum inhibition 65%. 
 Dana et al. 2015 evaluated the anti-angiogenic and antiproliferative effects of black 
pomegranate peel extract (PPE) on melanoma cell line. Angiogenesis was 
investigated by matrigel assay. HUVECs, vascular endothelial growth factor (VEGF) 
mRNA expression was detected by quantitative reverse transcriptase–polymerase 
chain reaction (QRT-PCR) assay. VEGF concentration in culture medium of 
HUVECs was determined by enzyme-linked immunosorbent assay (ELISA). PPE 
showed positive anti proliferative effect on melanoma cells in a dose-dependent 
manner, but not on HUVECs. The matrigel assay results indicated that PPE 
significantly inhibited length, size and junction of the tube like structures. VEGF 
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mRNA expression and concentration levels in culture medium of PPE treated 
HUVECs reduced significantly in a concentration-dependent manner. 
 Qasim et al. 2013 evaluated the effect of pomegranate seed oil and tamoxifen on 
breast cancer tumor marker (CA 15 - 3), aromatase enzyme, triglyceride (TG), 
cholesterol, and lactate dehydrogenase (LDH) in  mastectomy women. The results 
indicates tumor marker level was increase significantly in women without treament 
while tumor marker significally decreased in both pomegranate - tamoxifen 
combination.  LDH level was decreased in both groups when compared with 
untreated group.  
 Vakili and Sumanth 2016 evaluated the anti-proliferative and apoptotic effects of 
Punica granatum L. and Ziziphus mauritiana against carcinoma cells in-vitro and in-
vivo. In-vitro antioxidant activity of ethanol, aqueous and chloroform seed extracts of  
Punica grantum L and  Ziziphus mauritiana  showed that the ethanol extract of 
combination of both plants having significant Super oxide, Nitric oxide and ABTS 
scavenging activity with IC50 value of 32.79,31.95,78.85 µg/ml respectively. The MTT 
assay indicated that the percentage decrease of HeLa cells survival was found to be 
18.68% in 100 µg of ethanol extract of combination of Punica grantum L. 
and Ziziphus mauritiana and it also stimulated caspase-3 protease by 17.9-fold increase 
in DEVD-pNA cleavage. The ethanol extracts of combination of both plants induced 
chromosomal aberrations such as spindle disturbance, bridge chromosome, sticky 
chromosomes, and polar deviations in root tips of onions and also showed root growth 
inhibition activity at part with colchicine as standard and these differences were statistically non-
significant after 72h.Consequently. Synergic anticancer activity of ethanol extract of 
Punica grantum  L and Ziziphus mauritiana was proved. 
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 Dana et al. 2016   evaluated the role of peroxisome proliferator activated receptor 
alpha and gamma in anti-angiogenic effect of pomegranate peel extract (PPE). In this 
study the (PPARs) activation in the human umbilical resin endothelial cells 
(HUVECs) was evaluated. The mRNA expression level of vascular endothelial 
growth factor (VEGF) was detected by quantitative reverse transcription polymerase 
chain reaction (QRT-PCR). PPE significantly inhibited both tube formation (size, 
length and junction of tubes) and VEGF mRNA expression (p<0.05). Results showed 
that the anti-angiogenic effects of PPE were significantly reversed by PPAR 
antagonists. There was no difference between PPE Plus antagonists groups and 
control group. The results showed this effect of PPE could be mediated in part 
through PPAR dependent pathway. 
 Joseph et al. 2011 evaluated the antI-oxidant, anti-tumor and immunomodulatory 
properties of the polysaccharide (PSP001) isolated from fruit rind of Punica 
granatum. The anti- cancer properties of polysaccharide (PSP001) was evaluated on 
MCF-7 (breast cancer), KB (nasopharyngeal carcinoma) and K562( luekemia) cells 
by MTT assay. An IC50 value of 97.21 ± 1.06 µg/ml and 52.8 ± 0.9 µg/ml were 
obtained following 72 h incubation for MCF-7 and K562 cells, respectively. PSP001 
showed in-vitro growth stimulatory effect on isolated normal lymphocytes, and a 
proliferative index of 1.21 ± 0.01 at a concentration of 1000 µg/ml, indicating 
immunomodulatory activity.  
 Seidi   et al. 2016 evaluated anti-tumoral properties of the Punica granatum seed 
extract (PSE) in different human cancer cells.  Anti-proliferative properties of seed 
extract of PSE from human cancer cells was studied by MTT assay with A549 (lung 
non small cell carcinoma), MCF-7 (breast adenocarcinoma) SKOV3 (ovarian cancer 
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cells), pc3 (prostate adenocarcinoma). Results were compared to negative control at 
all test dose. SKOV3 ovarian cells were the most responsive to the anti proliferative 
effects of PSE with maximum growth inhibition and A549 ells are least responsive for 
cytotoxic effects. 
 Khan et al. 2013 evaluated the effect of Punica granatum fruit extract on 
angiogenesis  by using CAM assay and to verify either the extract is angiogenic or 
anti-angiogenic. A noticeable reduction in surface roughness of the blood vessels was 
observed. The diameter of tertiary, secondary and primary blood vessels was also 
reduced as compared to the blood vessels of control group CAM. The maximum 
effect was seen with 0.5% dilution. The study proved that Punica granatum 
(Pomegranate) fruit extract was anti-angiogenic and can be included in the studies for 
the development of new drug studies to treat cancer (as an anti-angiogenic agent). 
 Kawaii and Lansky 2004 evaluated the differentiation promoting activity of 
pomegranate fruit extract in HL-60 human promyelocytic leukemia cells. Flavonoid-
rich fractions from fresh (J) and fermented (W) pomegranate juice and from an 
aqueous extraction of pomegranate pericarps (P) were tested for potential 
differentiation-promoting agents in human HL-60 promyelocytic leukemia cells. Four 
assays were used to assess differentiation: nitro blue tetrazolium reducing activity, 
nonspecific esterase activity, specific esterase activity, and phagocytic activity. In 
addition, the effect of these extracts on HL-60 proliferation was evaluated. Extracts W 
and P were strong promoters of differentiation in all settings, with extract J showing 
only a relatively mild differentiation-promoting effect. The extracts had proportional 
inhibitory effects on HL-60 cell proliferation.  
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 Vakili and Sumanth 2016 evaluated in-vivo anti cancer activity of Punica granatum 
L and Ziziphus mauritiana using Ehrlich ascites carcinoma in Swiss albino mice. 
Experimental tumor was induced by inoculation of 1x10
6
 Ehrlich ascites carcinoma 
cells from the tumor bearing mice aseptically. A group of mice were administered 
aqueous, ethanol,chloroform extract of Punica grantum L of 200 mg/kg b.w, 
respectively, for nine days. Another group of mice were administered aqueous, 
ethanol, chloroform extract of Ziziphus mauritiana 200 mg/kg b.w, respectively for 
nine days. A group received combination combination of both plant extracts at a dose 
of 200 mg/kg.  Change in body weight, survival time, ascites fluid volume and packed 
cell volume were noted. At the end of study, 6 animals from each group were 
sacrificed, blood samples were collected and WBC, RBC, Hb content was estimated. 
Ethanol extract of combination of Ziziphus mauritiana and Punica grantum showed 
significant reduction in body weight, tumor volume, packed cell volume and 
percentage increase in life span. Significant increase in RBC, Hb content and 
reduction in WBC count were observed. 
 Nair   et al. 2011 evaluated the pomegranate extract (PE) on human pancreatic cancer 
cells. PAC-1 and As PC-1 human pancreatic cancer cell were used as in vitro models 
to test the effect of PE. PE treatment induced cell cycle arrest and inhibited cell 
proliferation in PANC-cells. PE was more effective in inhibiting the proliferation of 
PANC-1 cells than the clinically used dose of paclitaxel. Data suggest that PE is a 
promosing candidate for further preclinical testing for treatment of human pancreatic 
cancer. 
 Morrira et al. 2017 evaluated the anti-oxidant and cancer chemopreventive activities 
of Cistus and pomegranate polyphenols. Polyphenol rich extracts obtained from cistus 
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herb (Cistus incanus L.) and pomegranate peel (Punica granatum L.) exhibited 
significant antioxidant activity in V79 cell culture (Chinese hamster lung fibroblasts). 
Cistus extract reduced intracellular content of reactive oxygen species (ROS) by 30-
40% and pomegranate extract by 29-36%. In human breast (MCF-7) and colon 
(LOVO) cancer cell lines cistus and pomegranate extracts decreased cancer cell 
growth both in drug-sensitive cells by 15-30% and in drug resistant (doxorubicin- 
resistant; DX) sublines by 5-20%. Significantly higher proapoptotic impact of the 
extracts was observed in drug-sensitive than in drug-resistant sublines. The results 
suggest potential usefulness of the tested polyphenol rich extracts in people exposed 
to oxidative stress. 
 Hora et al. 2003 evaluated the chemopreventive effects of pomegranate seed oil on 
skin tumor development in CD mice. Two groups consisting each of 30, 4-5-week-
old, female CD (1) mice were used. Both groups had skin cancer initiated with an 
initial topical exposure of 7,12 dimethyl benzanthracene and with bi weekly 
promotion  using 12-O-tetraxe decanoylphorbol 13-acetate (TPA). Tumor incidence, 
tumor multiplicity were measured. Tumor incidence, the number of mice containing 
at least one tumor, was 100% and 93%, and multiplicity, the average number of 
tumors per mouse, was 20.8 and 16.3 per mouse after 20 weeks of promotion in the 
control and pomegranate seed oil-treated groups, respectively.  
In a second experiment, two groups each consisting of three CD (1) mice were 
used to assess the effect of pomegranate seed oil on TPA-stimulated ornithine 
decarboxylase (ODC) activity, an important event in skin cancer promotion. Each 
group received a single topical application of TPA, with the experimental group 
receiving a topical treatment 1 h prior with 5% pomegranate seed oil. The mice were 
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killed 5 h later, and ODC activity was assessed by radiometric method. The 
experimental group showed a 17% reduction in ODC activity. 
 Modaeinama et al. 2015 evaluated the anti-tumoral properties of Punica granatum 
peel (PPE) extract on different human cancer cells. The anti proliferative properties of 
peel extraxt of human cancer cells were evaluated. The cytotoxicity of different dose 
of PPE was evaluated by MTT assay with A549 (lung non small cell cancer), MCF-7 
(breast carcinoma) SKOV3 (ovarian cancer) and PC-3 (prostate adenocarcinoma) 
cells. In all studied cancer cells, PPE reduced the cell viablity to values below 40% 
even at the lowest doses. In all cases IC50 was determined at doses below 5 µg/ml. 
MCF-7 breast adenocarcinoma cell were the most responsive cells to anti proliferative 
effects of PPE with a maximum mean growth inhibition of 81% vs 69.9%, 69.4%, 
79.3% and 77.5% in SKOV3, PC-3 and A549 cells, respectively. Low doses of PPE 
exerted potential anti proliferative effects in different human cancer cells and its 
seems that (MCF-7 breast adenocarcinoma) cells are the most cells and SKOV3 
ovarian cancer cells the least responsive in this regard. 
 Adams et al. 2010 evaluated the pomegranate ellagitannin derived compounds on anti 
proliferative and anti aromatase activity in breast cancer cells in vitro. Estrogen 
stimulates the proliferation of breast cancer cell and growth of estrogen responsive 
tumors. A panel of ten ellagitannins (ET)-derived compounds including EA, gallagic 
acid (GA), and urolithins A and B (and their acetylated, methylated and sulfated 
analogs prepared in our laboratory) were examined for ability to inhibit aromatase 
activity and testosterone-induced breast cancer cell proliferation. Using a microsomal 
aromatase assay, the panel of ET-derived compounds were analyzed and it was 
identified that six compounds with anti-aromatase activity. Among these, urolithin B 
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(UB) was shown to most effectively inhibit aromatase activity in a live-cell assay.  
Proliferation assays also determined that UB significantly inhibited testosterone-
induced MCF-7aro cell proliferation. These studies suggest that pomegranate ET 
derived compounds have potential for the prevention of estrogen responsive breast 
cancers. 
 Motaal, and Shanker 2011 evaluated anti-cancer and anti-oxidant activities of 
standarized whole fruit, pulp and peel extract of Egyptian pomegrante. An HPLC 
method was modified and validated for standardisation using ellagic acid (EA) as a 
marker. The peel showed the highest anti-oxidant activity of (IC50=0.50) ± 0.9mg/ml) 
compared to other two extract, as well as pronounced anti cancer activity of against 
MCF-7 human breast cancer cell and HCT-116 colon cancer cell with IC50 values 7.7 
± 0.01 and 9.3 ± 0.06µg/ml respectively.  The standardized peel extract was 
formulated into capsules to develop natural pharmaceutical preparations.          
 
Chapter – III                                                                                             Aim and Objective 
 
Department of Pharmacology                                               The Erode College of Pharmacy  
60 
AIM AND OBJECTIVE 
Angiogenesis is a process of formation of new blood vessels from a pre-existing 
vasculature. It plays a vital role in embryonic development and numerous pathological 
conditions including cancer, rheumatoid arthritis, diabetes retinopathy, age related macular 
degeneration and neurological disorders such as Parkinsonism and Alzheimer‟s disease 
(Folkman 1990; Folkman 1995). In cancer, the growth and metastasis of tumour are 
dependent on angiogenesis (Hazel 2003). Cancer cells can generate various pro-angiogenic 
factors such VEGF, FGF, EGF. These factors promote the migration, proliferation and tube 
formation of endothelial cells which are essential steps for angiogenesis. The newly formed 
blood vessels can promote cancer growth by supplying nutrients, oxygen and most 
importantly facilitate cancer cell metastasis to other localities (Sassa and Hatta 2009; 
Homayouni 2009). In diabetic patients, hyperglycemia is the triggering factor for tissue 
alterations such as damage to capillary endothelial cells in the retina and BRB breakdown 
(Zhang et al. 2014; Brownlee 2005)
 
and one of the key players is vascular endothelial growth 
factor (VEGF), which promotes angiogenesis, abnormal vascular permeability, and 
eventually, an inflammatory response. Thus interrupting the process of angiogenesis has 
become one of the promising approaches in the treatment and prevention of cancer 
progression and diabetic retinopathy. 
Drug development from natural products has become a rapidly emerging and highly 
promising strategy to identify novel anti-angiogenic and anti-tumour agents. Plant derived 
compounds have played an important role in the development of several clinically useful 
anticancer agents. Over 62 % of biologically active substances currently used as anticancer 
agents are derived from natural sources, including plants, marine organism and 
microorganism. Today over 300 anti-angiogenic molecules targeting different signalling 
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pathways are being tested for their anticancer properties at preclinical and clinical stages 
(Sassa and Hatta, 2009; Homayouni, 2009). Although the results of clinical trials are 
encouraging the effects were modest (Lu and Bergers, 2013). Therefore, the search and 
discovery of novel anti-angiogenic principle that selectively target the angiogenic process 
could bring hope to millions of sufferers with cancer. 
Punica granatum belonging to family Punicaceae is more commonly known as 
pomegranate (Salgado et al. 2006). Punica granatum is a large shrub which grows 12-16 
feet, has many spiny branches with lance shaped glossy leaves. The bark of the tree turns 
gray as the tree ages. The flowers are large, red, white, or variegated having a tubular calyx 
that eventually becomes the fruit. Pomegranate is considered “A pharmacy unto itself” 
(Jurenka 2008). Pomegranate has many potential effects including bactericidal, antifungal, 
antiviral, immune modulation, vermifuge, stimulant, refrigerant, astringent, stomachic, 
styptic, laxative, diuretic and antihelminthic. It has also been widely used in treatment of 
cardiovascular diseases, diabetes, diarrhea, dysentery, asthma, bronchitis, cough, bleeding 
disorders, fever, inflammation, acquired immune deficiency syndrome, dyspepsia, ulcers, 
bruises, sores, mouth lesions, skin lesions, malaria, prostate cancer, atherosclerosis, 
hypertension, hyper lipidemia, denture stomatitis, male infertility, vaginitis, erectile 
dysfunction, Alzheimer's disease, obesity, and neonatal hypoxic-ischemic brain injury 
(Abdollahzdeh et al 2011; Jurenka 2008; Prakash et al. 2011). Punica granatum Linn roots 
are found to be rich in ellagitannins, including punicalin and punicalagin, numerous 
piperidine alkaloids (Tanaka et al. 1986; Neuhofer 1993). They are known for antihelmintic 
and vermifuge properties (Naqvi et al. 1991) and were found to be effective against 
melanoma in mice (Suresh et al. 2012). From the literature review, it was noted that fruit 
extract, peel extract (Dana et al. 2015) and pomegranate juice (Tibullo et al. 2016) possessed 
ant-angiogenic activity and it was noted that very limited study has been carried out in roots 
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of Punica granatum. Moreover, no scientific report is available regarding antiangiogenic and 
vasculoprotective potential of Punica granatum roots to the best of my knowledge.  Based on 
this, the present study was planned to evaluate anti-angiogenic and vaculoprotective property 
of Punica granatum roots in chorioallantoic membrane model. 
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PLAN OF WORK 
The present study was planned to evaluate the ant-angiogenic and vasculoprotective effect of 
Punica granatum root extract. The plan of work is 
 Collect fresh roots of Punica granatum from a healthy and fresh well grown tree. 
 To authenticate the roots of Punica granatum. 
 To shade dry and to powder the roots to a coarse material. 
 To extract the root powder using ethanol as solvent system by continuous hot 
extraction using soxhlet apparatus. 
 To evaluate the effect of crude ethanol extract on angiogenesis in chorioallantoic 
membrane (CAM) model.  
 Based on the activity of crude extract on vacularization in CAM model, the extract 
will be subjected to fractionation using solvents of increasing polarity. 
 The fractions will be evaluated for the effect on angiogenesis in chorioallantoic 
membrane (CAM) model.  
 The potent extract will be subjected to vasculoprotective role against glucose induced 
vascular changes. 
 The results will be statistically analyzed for significance using student t test and one 
way ANOVA followed by Dunnett‟s test.     
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MATERIALS AND METHODS 
The following instruments/apparatus were used for the present study 
Table 5:  Instrument and Apparatus were used                                               
S.no Instruments 
1 Autoclave 
2 BOD incubater 
3 Laminar flow 
4. pH meter 
5.  Digital balance 
6. Micropippete 
Plant Material 
 The root material of Punica granatum Linn. of family Punicaceae were collected from 
Agricultural field, Pudupattu village, Villupuram district, Tamilnadu, India. The plant 
material was taxonomically indentified, confirmed and authenticated by ABS Botanical 
garden  (AUT/ECP/109) was retained in our laboratory for further reference. The collected 
roots were shade dried and the dried materials were crushed to coarse powder with 
mechanical grinder. The powder was stored in an airtight container for extraction. 
Extraction 
 About 186 gms of powdered root material of Punica granatum were extracted with 
800 ml of ethanol in soxhlet apparatus for 72 hours. After extraction, the solvents were 
removed by distillation and evaporated to obtain crude extract of Punica granatum roots. 
Phytochemical screening 
 The extract obtained was subjected to preliminary phytochemical screening (Kokate, 
1994; Rosenthaler, 1930) 
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Detection of alkaloids  
 Individually the extracts were dissolved in dilute Hydrochloric acid and filtered. The 
filtered extract was subjected to detection of alkaloids. 
Mayer’s Test 
 Filtrates were treated with Mayer‟s reagent (Potassium Mercuric Iodide). The 
formation of a yellow coloured precipitate indicates the presence of alkaloids.  
Wagner’s Test 
 Filtrates were treated with Wagner‟s reagent (Iodine in Potassium Iodide). The 
formation of brown/reddish precipitate indicates the presence of alkaloids.  
Dragendroff’s Test 
 Filtrates were treated with Dragendroff‟s reagent (solution of Potassium Bismuth 
Iodide). The formation of red precipitate indicates the presence of alkaloids.  
Hager’s Test 
 Filtrates were treated with Hager‟s reagent (saturated picric acid solution). The 
formation of yellow coloured precipitate indicates alkaloids. 
Detection of carbohydrates 
 The extracts were dissolved individually in 5 ml distilled water and filtered. The 
filtrates were used to test for the presence of carbohydrates.  
Molisch’s Test 
 Filtrates were treated with 2 drops of alcoholic α-naphthol solution in a test tube.  The 
formation of the violet ring at the junction indicates the presence of Carbohydrates.  
Benedict’s Test 
 Filtrates were treated with Benedict‟s reagent and heated gently. Orange red 
precipitate indicates the presence of reducing sugars.  
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Fehling’s Test 
 Filtrates were hydrolysed with dil Hcl, neutralized with alkali and heated with 
Fehling‟s A & B solutions. The formation of red precipitate indicates the presence of 
reducing sugars.  
Detection of glycosides 
 Individually the extracts were hydrolysed with dil. HCl, and then subjected to test for 
glycosides.  
Modified Borntrager’s Test 
 The extracts were treated with Ferric Chloride solution and immersed in boiling water 
for about 5 minutes. The mixture was cooled and extracted with equal volumes of benzene. 
The benzene layer was separated and treated with ammonia solution. Formation of rose-pink 
colour in the ammonical layer indicates the presence of anthranol glycosides.  
Legal’s Test  
 The extracts were treated with sodium nitropruside in pyridine and sodium hydroxide. 
The formation of pink to blood red colour indicates the presence of cardiac glycosides.  
Keller Killiani Test 
 Small portion from the extract was shaken with 1ml of Glacial acetic acid containing 
trace of ferric chloride. 1ml of Conc H2So4 was added carefully by the sides of the test tube. 
A blue colour in the acetic acid layer and red color at the junction of two liquids indicate the 
presence of glycosides. 
Detection of saponins  
Froth Test 
 Extracts were diluted with distilled water to 20ml and this was shaken in a graduated 
cylinder for 15 minutes. Formation of 1 cm layer of foam indicates the presence of saponins.  
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Foam Test 
 0.5 gm of extract was shaken with 2 ml of water. If foam produced persists for ten 
minutes it indicates the presence of saponins.  
Detection of phytosterols  
Salkowski’s Test  
Extracts were treated with chloroform and filtered. The filtrates were treated with few drops 
of Conc. Sulphuric acid, shaken and allowed to stand. Appearance of golden yellow colour 
indicates the presence of triterpenes.  
Libermann Burchard’s test 
 Extracts were treated with chloroform and filtered. The filtrates were treated with few 
drops of acetic anhydride, boiled and cooled. Conc. Sulphuric acid was added. Formation of 
brown ring at the junction indicates the presence of phytosterols.  
Detection of phenols  
Ferric Chloride Test  
 Extracts were treated with 3-4 drops of ferric chloride solution. Formation of bluish 
black colour indicates the presence of phenols.  
Detection of tannins  
Gelatin test 
 To the extract 1% gelatin solution containing sodium chloride was added. Formation 
of white precipitate indicates the presence of tannins.  2ml of filtrate, few drops of lead 
acetate solution were added in a test tube. Formation of yellow precipitate indicates the 
presence of Tannins. 
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Detection of flavonoids  
Alkaline Reagent Test  
            Extracts were treated with few drops of sodium hydroxide solution. Formation of 
intense yellow colour, which becomes colourless on addition of dilute acid, indicates the 
presence of flavonoids.  
Lead acetate test 
 Extracts are treated with few drops of lead acetate solution. Formation of yellow 
colour precipitate indicates the presence of flavonoids. 
Detection of proteins and aminoacids  
Ninhydrin Test 
 To the extract, 0.25% w/v ninhydrin reagent was added and boiled for few minutes. 
Formation of blue colour indicates the presence of amino acid.  
Xanthoproteic test 
 The extracts were treated with few drops of concentrated nitric acid. Formation of 
yellow colour indicates the presence of proteins.  
Detection of Fixed oils and Fats  
Oily Spot Test 
 One drop of extract was placed on filter paper and the solvent was evaporated. An 
oily stain of filter paper indicates the presence of fixed oil. 
Quantitative estimation of bioactive compounds in crude ethanol extract of Punica 
granatum roots 
Determination of phenolic content 
Principle 
This method strongly relies on the reduction of the mixture heteropolyphospho 
tungsates-molybdates by the phenolic compound which results in the formation of blue 
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coloured chromogen. The phenolic compounds react with folin-ciocalteu reagent only under 
basic conditions adjusted by sodium carbonate solution. Under basic conditions, it has been 
observed that the phenolic compounds undergoes dissociation to form a phenolate anion 
which reduces the folin-ciocalteu reagent ie the mixture of tungstates and molybdates 
rendering a blue coloured solution. The coloured intensity of the formed blue chromogen can 
be measured by the absorbance reading using spectrophotometic. 
Procedure 
 The total phenolic content was determined spectrophotometrically using the Folin–
Ciocalteu method. It is based on the oxidation of phenolic groups by phosphomolybdic and 
phosphotungstic acids (FC reagent). This method, based on the Slinkard and Singleton, 1977  
and the early work of Singleton & Rossi, 1965  is a colorimetric oxidation/reduction method 
for phenolic compounds. A blue colour which is the product of metal oxidation, that exhibits 
a broad light absorption with a maximum at 764 nm. The intensity of light absorption is 
proportional to the concentration of phenols. 20 μL of the diluted sample was added to 100 
μL of Folin-Ciocalteu reagent. After 8 min, 300 μL of saturated sodium carbonate solution 
(25%) was added. The absorbance was measured at 764 nm. The calibration curve was 
prepared with gallic acid solutions ranging from 10 to 1000 μg/ml, and the results are given 
as gallic acid equivalents (GAE). 
Determination of total flavonoids  
Principle 
This method is based on the formation of the flavonoid aluminium complex which has 
an absorptivity maximum at 415nm. The principle of the method used for the determination 
of  flavonoid content consist in the fact that AlCl2 forms stable acid complexes with carbonyl 
group at C4 and hydroxyl group at C3 and C5 in flavanols and flavones. In addition it forms 
acid labile complexes with hydroxyl in the orthoposition in A or B rings of flavonoids. 
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Procedure 
Flavonoid content was measured using aluminium chloride colorimetric method. 
Various concentrations of extract were mixed with 0.1 ml of 10 % aluminium chloride (w/v), 
0.1 ml of 1 M potassium acetate and 2.8 ml distilled water. The mixture was allowed to stand 
at room temperature for 30 minutes. The absorbance of reaction mixture was measured at 415 
nm. Results are expressed as mg/g quercetin equivalent (Chang, 2002). 
Evaluation of total antioxidant capacity by Phosphomolybdenum method 
Principle 
Antioxidant present in the sample reduce the MO(VI) to MO (V), which then react 
with phosphate group of sodium phosphate to form green coloured MO(V)- phosphate 
complex (phosphomolybdenum complex) in an acidic medium. This complex is then 
spectrophotometrically measured at 695nm. This reaction is highly time dependent. 
Procedure 
 The antioxidant activities extract was evaluated by the phosphomolybdenum method 
according to the procedure described by Prieto et al., 1999. The assay is based on the 
reduction of Mo (VI) – Mo (V) by the extract. The subsequent formation of a green 
phosphate/Mo (V) complex at acid pH. 0.3 ml different concentrations of extract (10μg/ml to 
200 μg/ml) were mixed with 3 ml of reagent solution (0.6 M sulfuric acid, 28 mM sodium 
phosphate and 4 mM ammonium molybdate). 0.3 mL of methanol was used as blank  in place 
of extracts. The tubes were incubated in a boiling water bath at 95°C for 90 min. The 
absorbance of the solution was measured at 695 nm after cooling to room temperature. The 
antioxidant capacity of each sample was expressed as ascorbic acid equivalent. 
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Determination of free radical scavenging activity  
 DPPH radical scavenging assay 
Principle 
DPPH is a stable nitrogen centered free radical which can accept an electron or 
hydrogen radical to become a stable diamagnetic molecule. Any molecule that can donate an 
electron or hydrogen to DPPH can react with it thereby bleach the DPPH absorption. DPPH 
is a purple colour dye having absorbtion maximum of 517 nm and upon reaction with 
hydrogen donar, the purple colour fades or disappears due to conversion to 2, 2-diphenyl-1-
picryl hydrazine resulting in decrease in absorbance. Substances which are able to perform 
the reaction can be considered as antioxidant and therefore radical scavengers. 
Procedure 
 Free radical scavenging activity was determined spectrophotometrically using the 
method of Blois, 1958. This method is based on the measurement of the reducing ability of 
antioxidants toward the DPPH radical. Briefly, 100 μl of various concentrations of the root 
extract (1.95 μg/ml to 1000 μg/ml) in methanol were added to 10 ml of a methanol solution 
of DPPH (1.01.10
-2
 M). The mixture was allowed to stand at room temperature for 30 min in 
the dark after a vigorous shake. The absorbance was measured at 517 nm. The control 
mixture consists of 100 μl of methanol and 10 ml of DPPH solution. The scavenging activity 
on the DPPH radical was calculated as inhibition percentage using the following equation: 
% Inhibition = [(AB − AS)/AB] × 100 
 where AB is the absorbance of the control reaction (containing all reagents except the 
test compound), and AS is the absorbance of the test compound. Ascorbic acid was used as 
reference standard. The tests were carried out in triplicate. The extract concentration 
providing 50% inhibition (IC50) was calculated from the graph of inhibition percentage 
plotted against extract concentration. 
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Ferric reducing antioxidant capacity  
Principle 
The reducing capacity of the compound can be measured by direct reduction of 
Fe[(CN)6]3 to Fe[(CN)6]2. Addition of free Fe
3+ 
to the reduced product leads to formation of 
intense Perl‟s prussion blue complex, Fe4[(CN)6]3, which has a strong absorbance at 700 nm. 
An increase in absorbance of the reaction mixture would indicate an increase in the reducing 
capacity due to an increase in the formation of the complex. In this assay, the yellow colour 
of the test solution changes to various shades of green and blue depending upon the reducing 
power of antioxidant samples.  
Procedure 
 According to the method described by Oyaizu, 1986 the reducing powers of extract 
were determined. Different concentrations of root extract (1.95 μg/ml to 1000 μg/ml) in 1 ml 
of distilled water were mixed with phosphate buffer (2.5 ml, 0.2 M, pH 6.6) and potassium 
ferricyanide [K3Fe(CN)6] (2.5 mL, 1%). After incubation at 50°C for 20 min 2.5 ml of 
trichloroacetic acid (10%) was added to the mixture and centrifuged at 3000 rpm for 10 min. 
The supernatant layer of the solution (2.5 ml) was mixed with distilled water (2.5 ml) and 
FeCl3 (0.5 ml, 0.1%) and the absorbance was measured at 700 nm. Increased absorbance of 
the reaction mixture indicates increased reducing power. Ascorbic acid was used as reference 
standard.  
Effect of crude ethanol extract of Punica granatum roots on vascularisation in chick 
chorioallantoic membrane (CAM) model 
Fertile chicken eggs (Gallus domesticus) were obtained from poultry farm in 
Namakkal district and were kept in a humidified incubator at 37C in horizontal position. The 
eggs were rotated three times a day to ensure uniform embryo development. On day 3, eggs 
were swabbed with 70 % alcohol.  Under a laminar flow hood, 2–3 ml of albumin was 
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aspirated from eggs with a syringe without needle through a small hole drilled at the narrow 
end of the eggs, allowing the developing CAM to detach from the shell membrane. The holes 
were then closed with plaster. The upper surface of the shell was then cut to make a window 
with a sterile forceps under laminar air flow. This window served as a portal of access for the 
CAM. The window was then closed with a cellophane tape and the eggs were returned to the 
incubator. On day 8,   the window was opened and the CAM was accessed and photographed 
and the eggs were grouped into four groups of six each.  Absorbable gelatin sponge soaked in 
100 μg of crude ethanol extract of Punica granatum in PBS was placed directly using 
surgical forceps on CAM surface to one group of eggs. To another group of eggs, absorbable 
gelatin sponge soaked in 200 μg of crude ethanol extract of Punica granatum in PBS was 
placed directly using surgical forceps on CAM surface. A group of eggs served as solvent 
control in which absorbable gelatin sponge soaked in 0.5 μl of PBS was placed on CAM 
surface and a group served as normal egg without treatment to access angiogenesis. All the 
eggs were then returned to the incubator. The experiments were performed between days 8 
and 12 of incubation period because, it is generally accepted that days 8 to 10 are strongly 
angiogenic. On day 12 of incubation, the CAM was inspected for microvessel density. The 
blood vessels were counted including the vessels radially converging towards the center in an 
area of 80 mm×80 mm around the sponge using Photoshop Elliptical Marquee tool (Nguyen 
et al., 1994; Tufan and Satiroglu-Tufan, 2005; Koneri et al., 2014).. 
The percentage inhibition was calculated using the following equation 
Percentage inhibition = Vessel number of CAM treated by normal saline - Vessel number of 
CAM treated by extract / Vessel number of CAM treated by normal saline X 100.   
Based on the results obtained from the effect of crude extract of Punica granatum 
roots on vascularisation in chick chorioallantoic membrane (CAM) model, the extract is 
subjected to fractionation. 
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Figure. 18  Vascularisation in chick chorioallantoic membrane (CAM) Model. 
A. window made in the egg shell of a 3-day-old chick embryo 
B Diagram of the technique  
C. filter paper discs/gelatin sponge with the test substances placed manually 
by surgical forceps onto the CAM of a 8-day-old chick embryo 
Fractionation of crude extract of Punica granatum roots.  
About 4 g of the dried ethanol extract was dissolved in 20 ml water and was 
successively partitioned with petroleum ether, chloroform, ethyl acetate and n-butanol. The 
percentage yield of the resulting extracts were calculated and shown in table --.  Crude extract 
and fractions were encoded as: CE – Crude ethanol Extract; PEF- Petroleum Ether Fraction; 
CF- Chloroform Fraction; EAF- Ethyl Acetate Fraction; BF- n-butanol fraction; AF- 
Aqueous Fraction remaining after fractionation. All extract fractions were freeze dried and 
stored at 4°C (Magaji et al., 2007). 
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                                               Crude Methanol extract (4 g) 
                                                           Water (20 ml) 
                                                           Petroleum ether (20 ml X 3) 
 
 
                              Petroleum ether fraction (0.13 g)      Aqueous 
                                                                                        Chloroform (20 ml X 3)  
 
                                                                
                                                                      Chloroform fraction (0.05 g)            Aqueous 
 Ethyl acetate (20 ml X 3) 
 
 
                                                                   Ethyl acetate fraction (0.06 g)                 Aqueous 
                                                                                                                  n-butanol (20 ml X 3) 
 
 
                                                 n-butanol fraction (0.41 g)                Aqueous fraction (2.96 g)  
                        
Fractionation scheme of Punica granatum roots 
 
Angiogenesis inhibitory effects of various fractions from crude ethanol extract of Punica 
granatum roots 
Thirty Fertile chicken eggs (Gallus domesticus) were used for the evaluation of 
angiogenesis inhibitory effects of various fractions from crude ethanol extract of Punica 
granatum.  The eggs were rotated three times a day to ensure uniform embryo development. 
On day 3, eggs were swabbed with 70 % alcohol.  Under a laminar flow hood, 2–3 ml of 
Chapter – V                                                                                         Materials and Methods 
 
Department of Pharmacology                                               The Erode College of Pharmacy  
76 
albumin was aspirated from eggs with a syringe without needle through a small hole drilled at 
the narrow end of the eggs, allowing the developing CAM to detach from the shell 
membrane. The holes were then closed with plaster. The upper surface of the shell was then 
cut to make a window with a sterile forceps under laminar air flow. This window served as a 
portal of access for the CAM. The window was then closed with a cellophane tape and the 
eggs were returned to the incubator. On day 8, the window was opened and the CAM was 
accessed and photographed and the eggs were grouped into five groups of six each for 
evaluation of five fractions. Absorbable gelatin sponges soaked in 100 μg of various fractions  
were placed directly using surgical forceps on CAM surface to respective group of eggs. All 
the eggs were then returned to the incubator. On day 12 of incubation, the CAM was 
inspected for microvessel density. The vessels were counted and the percentage inhibition 
was calculated (Nguyen et al., 1994; Tufan and Satiroglu-Tufan, 2005; Koneri et al., 2014). 
Effect of Ethyl acetate fraction of Punica granatum on hyperglycemia induced vascular 
changes in chick chorioallantoic membrane model 
Fertile chicken eggs (Gallus domesticus) were obtained from poultry farm and were 
incubated at 38° C in a humidified environment in horizontal position. The eggs were rotated 
three times a day to ensure uniform embryo development.  On day 3, eggs were swabbed with 
70 % alcohol. Under a laminar flow hood, 2 ml of albumin was aspirated from eggs with a 
syringe through a small hole drilled at the narrow end of the eggs, allowing the developing 
CAM to detach from the shell membrane. The holes were then closed with plaster. The upper 
surface of the shell was then cut to make a window with a sterile forceps under laminar air 
flow. The window was then closed with a sterile transparent tape and the eggs were returned 
to the incubator. By day 8 of post incubation, thirty eggs were selected for experiment and 
divided into five groups of six each. Group I vehicle control eggs received a single 
intravitellus injection of 1 ml sterile water. In group II eggs, hyperglycemia was induced by a 
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single intravitellus injection of 5 mg glucose/g whole egg (Glucose stock solution: 30 % w/v 
in water). Group III eggs received 100 µg EAF-PG dissolved in glucose solution (5 mg 
glucose/g whole egg). On day 12 of incubation, blood glucose level was measured in the 
samples taken from the CAM vessel using Accu-check glucometer and the blood vessels 
were inspected for any vascular change/abnormalities in the respective groups (Larger et al. 
2004; Di Marco et al. 2008). The CAM was inspected and photographed using a digital 
camera with a magnification of 20 X. The blood vessels were counted including the vessels 
radially converging towards the center in an area of 80 mm×80 mm around the sponge using 
Photoshop Elliptical Marquee tool. 
Statistical analysis 
 The data‟s were expressed as mean ± standard error of the mean (SEM). For paired 
comparisons, student's t-test analyses were performed. Different groups were assessed by 
one-way analysis of variance (ANOVA) for multiple comparisons followed by dunnett's test 
(Graphpad software Inc, La Jolla, CA. Trial version 5). The criterion for statistical 
significance was set at P < 0.05. 
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Table. 6 Percentage yield of ethanol extract of Punica granatum root (EEPG) 
S.NO Extract 
Percentage Yield   
(w/w) 
 
1 
 
Crude ethanol extract of  Punica granatum root 
                               (EEPG) 
 
42.86 % 
 
186 g of dried powder of Punica granatum root yielded 79.70 g of crude ethanol 
extract (EEPG) which was about 42.86 % of the root powder subjected to extraction.  
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Table.7 Qualitative phytochemical screening of EEPG 
 
Phytochemicals Test EEPG 
Alkaloids a. Mayer‟s test 
b. Dragendroff‟s 
c. Hager‟s test 
d. Wagner‟s test 
+ 
+ 
- 
+ 
      Phytosterols    
And  
Triterpenes    
a. Leiberman-Burchard 
 
b. Salkowaski test 
 
- 
 
- 
Flavonoids 
a. Alkaline reagent test 
b. Lead acetate test 
+ 
+ 
Saponins a. Foam test + 
Proteins 
and Aminoacids 
a. Ninhydrin test 
b. Xanthoproteic test 
- 
+ 
 
Phenolics  a. Ferric chloride test 
 
+ 
 
Tannins a. Gelatin test + 
Carbohydrate a. Molisch test 
b. Fehling‟s test 
c. Benedict‟s test 
+ 
+ 
+ 
Gylcosides a. Modified   Borntrager‟s test 
b. Legal‟s test 
c. Keller-Killiani test 
+ 
- 
+ 
  Presence (+) Negative (-) 
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Table.8 Total Phenolic content (TPC), Total Flavonoid content (TFC) and Total 
antioxidant capacity (TAC) of EEPG 
 
Extract TPC 
(μg of GAE/mg of 
extract) 
TFC 
(μg of 
quercetin/mg of 
extract) 
TAC 
(μg  of  quercetin 
/mg of extract) 
 
EEPG 
 
237.60 
 
247.60 
 
441.01 
  
  
 Total Phenolic content (TPC) is expressed as milligram of gallic acid equivalent per 
gram of sample. Total tannin content (TTC) is expressed as milligrams of tannic acid 
equivalents per gram of dry extract. Total Flavonoid content (TFC) is expressed as 
milligrams of quercetin equivalents per gram of dry extract. Total antioxidant capacity is 
expressed as milligrams of quercetin equivalents per gram of dry extract. 
Table.9 Free radical scavenging activity of EEPG 
 
 
Extract 
 
DPPH radical scavenging 
(μg/mL) 
IC50 
Nitric oxide 
scavenging 
activity 
( μg/mL) 
IC50 
 
EEPG 
 
114 
 
389 
 
 
Standard 
 
15.52 
 
12 
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Figure.19 DPPH SCAVENGING ACTIVITY 
 
 
 
 
 
 
 
 
 
 
 
 
Figure.20 NITRIC OXIDE SCAVENGING ACTIVITY 
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Figure.21 FERRIC REDUCING ANTIOXIDANT CAPACITY 
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                                               Figure.22 (a) Normal control                                                                 
 
 
 
 
 
 
 
 
 
 
 
 
Figure.22 (b) PBS control 
 
Chapter – VI                                                                                      Results and Discussion 
 
Department of Pharmacology                                      The Erode College of Pharmacy    
84 
 
 
 
 
 
 
 
 
 
 
               
 
          Figure 22 (c) EEPG (100 µg)                                                        
 
 
 
 
 
 
 
 
 
 
 
                         Figure 22 (d)           EEPG (100 µg) 
               Figure.22 Effect of EEPG extract on vascularisation in chick chorioallantoic 
membrane (CAM) mode 
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Table.10 Effect of EEPG extract on vascularisation in chick chorioallantoic membrane 
(CAM) model 
  
Treatment 
 
Average Vessel Number  
 
 
Normal Egg 
 
59.67 ± 1.52 
 
PBS Control 
 
                          57.83 ± 1.16
ns a 
 
EEPG (100 µg)                                                        
                       
14.67 ± 0.66
*** b
  
 
All values are expressed as mean ± S.E.M, n=6 in each group.  
a 
Values are significantly different from normal control group; ns-non significant; *P < 0.05;  
**P < 0.01; ***P < 0.001. (Student t test analysis)  
b
Values are significantly different from PBS control group; ns-non significant; *P < 0.05;  
**P < 0.01; ***P < 0.001. (Student t test analysis)  
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Figure.23 Effect of EEPG extract on vascularisation in chick chorioallantoic membrane 
(CAM) model 
All values are expressed as mean ± S.E.M, n=6 in each group.  
a 
Values are significantly different from normal control group; ns-non significant; *P < 0.05;  
**P < 0.01; ***P < 0.001. (Student t test analysis)  
b
Values are significantly different from PBS control group; ns-non significant; *P < 0.05;  
**P < 0.01; ***P < 0.001. (Student t test analysis)  
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Fractionation of crude extract 
 
Table.11 The percentage yield of various fractions of Punica granatum root extract 
 
S.No Extract/Fractions Percentage Yield (w/w) 
1 Petroleum ether Fraction (PEF-PG) 3.25 % 
2 Chloroform Fraction (CF-PG) 1.25 % 
3 Ethyl acetate Fraction (EAF-PG) 1.5 % 
4 n-Butanol Fraction (BF-PG) 10.25 % 
5 Aqueous Fraction (AF-PG) 74 % 
  
Fractionation of 4 g methanol extract using petroleum ether as solvent yielded 0.13 g 
which was about 3.25 % of the extract subjected to fractionation. Successive fractionation 
with chloroform yielded 0.05 g, which was about 1.25 % of the extract subjected to 
fractionation. Successive fractionation with ethyl acetate yielded 0.06 g, which was about 1.5 
% of the extract subjected to fractionation. Successive fractionation with n-butanol yielded 
0.41 g, which was about 10.25 % of the extract subjected to fractionation. The remaining 
aqueous fraction after fractionation yielded 2.96 g, which was about 74 % of the extract 
subjected to fractionation. All extract fractions were freeze dried and stored at 4 C. 
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Figure 24 (a) 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 24 (b) 
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Figure 24(c) 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 24(d) 
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Figure 24 (e) 
Figure. 24 Effect of various fractions from EEPG on vascularization in chick 
chorioallantoic membrane (CAM) model 
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Table.12  Effect of various fractions from EEPG on vascularisation in chick 
chorioallantoic membrane (CAM) model 
Treatment Average Vessel Number  
Normal Egg 59.67 ± 1.52 
PBS Control 57.83 ± 1.16
ns a 
PEF-PG 47.33 ± 1.25
*** b 
CF-PG 29.00 ± 0.96
*** b  
EAF-PG 20.33 ± 0.76
*** b
 
BF-PG 32.17 ± 0.65
*** b
 
 
AF-PG 28.67 ± 0.66
*** b
 
 
 
All values are expressed as mean ± S.E.M, n=6 in each group.  
a 
Values are significantly different from normal control group; ns-non significant; *P < 0.05;  
**P < 0.01; ***P < 0.001. (Student t test analysis)  
b 
Values are significantly different from PBS control group; ns-non significant; *P < 0.05;  
**P < 0.01; ***P < 0.001. (One -way ANOVA followed by Dunnett‟s test was used to 
compare experimental groups). 
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Figure.25 Effect of various fractions from EEPG on vascularisation in chick 
chorioallantoic membrane (CAM) model 
 
All values are expressed as mean ± S.E.M, n=6 in each group.  
a 
Values are significantly different from normal control group; ns-non significant; *P < 0.05;  
**P < 0.01; ***P < 0.001. (Student t test analysis)  
b 
Values are significantly different from PBS control group; ns-non significant; *P < 0.05;  
**P < 0.01; ***P < 0.001. (One -way ANOVA followed by Dunnett‟s test was used to 
compare experimental groups). 
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Figure 26 (a) 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 26 (b)    Hyperglycaemia induced (5 mg glucose/g whole egg) 
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 Hyperglycaemia induced (5 mg glucose/g whole egg) 
 
 
 
 
 
 
 
 
 
 
 
Figure 26 (c)   Hyperglycemia induced (5 mg glucose/g whole egg) + EAF-PG 
Figure.26 Effect of Ethyl acetate fraction of Punica granatum on hyperglycemia induced 
vascular changes in chick chorioallantoic membrane model. 
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Table.13 Effect of EAF-PG extract on vascularisation in hyperglycemia induced chick 
chorioallantoic membrane model 
 
Treatment 
 
Average Vessel Number  
 
 
Sterile water 
 
31.00 ± 0.96 
 
Glucose 5 mg/g of whole egg 
 
                          54.00 ± 1.23
*** a 
 
Glucose + EAF-PG 100 µg                                                       
                       
42.33 ± 1.05
** b
  
All values are expressed as mean ± S.E.M, n=6 in each group.  
a 
Values are significantly different from sterile water (vehicle) group; ns-non significant;  
*P < 0.05; **P < 0.01; ***P < 0.001. (Student t test analysis)  
b
Values are significantly different from Glucose induced group; ns-non significant; *P < 
0.05;  
**P < 0.01; ***P < 0.001. (Student t test analysis)  
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 Figure.27 Effect of EAF-PG extract on vascularisation in hyperglycemia induced 
chick  chorioallantoic membrane model 
All values are expressed as mean ± S.E.M, n=6 in each group.  
a 
Values are significantly different from sterile water (vehicle) group; ns-non significant;  
*P < 0.05; **P < 0.01; ***P < 0.001. (Student t test analysis)  
b
Values are significantly different from Glucose induced group; ns-non significant; *P < 
0.05;  
**P < 0.01; ***P < 0.001. (Student t test analysis)  
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Table.14 Effect of EAF-PG extract on blood glucose level in hyperglycemia induced 
CAM 
Group Blood glucose 
(mg/dl) 
 
Sterile water 
73.50 ± 1.25 
 
Glucose 5 mg/g of whole egg 
 
304.8 ± 2.85
***
a 
 
Glucose + EAF-PG 100 µg                                                       
 
117.0 ± 2.63
***b 
 
All values are expressed as mean ± S.E.M, n=6 in each group.  
a
 values are significantly different from group II Vehicle control ; ns – non-significant; P 
values: 
* 
p< 0.05, 
** 
p< 0.01, 
*** 
p< 0.001 (Student t. test analysis). 
b
 values are significantly different from group III glucose induced, ns- non significant, P 
values: 
* 
p<0.05, 
** 
p< 0.01, 
*** 
p< 0.001 (one way ANOVA followed by Dunnett‟s test). 
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Fig. 28 Effect of EAF-PG extract on blood glucose level in hyperglycemia induced CAM 
All values are expressed as mean ± S.E.M, n=6 in each group.  
a
 values are significantly different from group II Vehicle control ; ns – non-significant; P 
values: 
* 
p˂ 0.05, ** p˂ 0.01, *** p˂ 0.001 (Student t. test analysis). 
b
 values are significantly different from group III glucose induced, ns- non significant, P 
values: 
* 
p˂ 0.05, ** p˂ 0.01, *** p˂ 0.001 (one way ANOVA followed by Dunnett‟s test). 
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Percentage yield 
The percentage yield of ethanol extract of Punica granatum root (EEPG) is shown in 
table 6.  186 g of dried leaf powder yielded 79.70 g of crude ethanol extract (CME-OT), 
which was about 42.86 % of the root powder subjected to extraction.  
Phytochemical examination 
Qualitative phytochemical screening of EEPG is shown in table.7. The phytochemical 
examination of EEPG revealed the presence of alkaloids, glycosides, flavonoids, tannins, 
saponins and carbohydrates. 
Quantitative estimation of bioactive compounds 
Total Phenolic content 
The quantitative estimation of bioactive compounds in EEPG is shown in table. 8. 
The total phenolic content in EEPG was determined spectrophotometrically using folin-
ciocalteu method and the results are expressed as gallic acid equivalents (GAE). 
The total phenolic content in EEPG was found be 237.60 μg of GAE equivalent/mg of 
extract. 
Total Flavonoid content 
The total flavonoid content was determined by aluminium chloride calorimetric 
method and the results were expressed as quercetin equivalent. The total flavonoid content in 
EEPG was found be 247.60 μg of quercetin equivalent/mg of extract (Table.8). 
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Total antioxidant capacity 
The total antioxidant capacity of EEPG was evaluated by phosphomolybdinum 
method and the results were expressed as quercetin equivalent. EEPG roots showed 441.01 
μg of quercetin equivalent/mg of extract antioxidant activity (Table.8). 
Free radical scavenging 
The free radical scavenging activity of EEPG were investigated using DPPH 
scavenging activity, Nitric oxide scavenging activity and ferric reducing assay. 
DPPH scavenging activity 
The DPPH radical scavenging activity of EEPG are shown in table.9 and figure.19.  A 
dose dependent inhibition of DPPH activity was observed with crude extract. The IC50 
concentration of EEPG which caused inhibition of DPPH radical was 114 μg/ml.  
As lower IC50 values indicate higher radical scavenging activity, DPPH showed a potent 
DPPH radical scavenging activity. 
Nitric oxide scavenging activity 
The nitric oxide scavenging activity of EEPG is shown in table.9 and figure 20.  A 
dose dependent inhibition of nitric oxide formation was observed with crude extract. The IC50 
concentration of EEPG which caused inhibition of nitric oxide radical was 389 μg/ml and the  
Ferric reducing power assay 
The ferric reducing power of EEPG are shown in figure. 21. It was observed that, 
EEPG showed a concentration dependent increase in reducing capacity. 
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Effect of EEPG root on vascularisation in chick chorioallantoic membrane (CAM) 
model 
  The effect of EEPG on vascularisation in chick chorioallantoic membrane (CAM) 
model is shown in table.10 and figure.22- figure.23. It was observed that, the microvessel 
density was significantly (p<0.001) decreased on day 12 of inspection in group of fertile 
chicken eggs incubated at 37C in presence of EEPG (100 µg) placed on CAM surface on 8th 
day of incubation compared to PBS solvent control group of eggs. The average number of 
vessels observed on CAM surface in eggs incubated with PBS solvent control was found to 
be 57.83 ± 1.16. Whereas in eggs treated with EEPG, the number of vessels were reduced to 
14.67 ± 0.66
 
(p<0.001).  
  Based on these results, EEPG extract was subjected for fractionation to 
evaluate the effect of fractions on angiogenesis in chorioallantoic membrane.  
Percentage yield of various fractions of CME-PA 
The Percentage yield of various fractions of EEPG is shown in table.11. Fractionation 
of 4 g methanol extract using petroleum ether as solvent yielded 0.13 g which was about 3.25 
% of the extract subjected to fractionation. Successive fractionation with chloroform yielded 
0.05 g, which was about 1.25 % of the extract subjected to fractionation. Successive 
fractionation with ethyl acetate yielded 0.06 g, which was about 1.5 % of the extract 
subjected to fractionation. Successive fractionation with n-butanol yielded 0.41 g, which was 
about 10.25 % of the extract subjected to fractionation. The remaining aqueous fraction after 
fractionation yielded 2.96 g, which was about 74 % of the extract subjected to fractionation. 
All extract fractions were freeze dried and stored at 4 C. 
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Angiogenesis inhibitory effects of various fractions from EEPG in chick chorioallantoic 
membrane (CAM) model 
The effect of various fractions from EEPG in chick chorioallantoic membrane (CAM) 
model is shown in table 12, figure 24 and 25. On day 12 of inspection, it was observed that 
the group of eggs treated with PEF-PG showed 47.33 ± 1.25 average number of vessels on 
CAM. The eggs treated with CF-PG showed 29.00 ± 0.96 average number of vessels on 
CAM. The eggs treated with EAF-PG showed 20.33 ± 0.76 average number of vessels on 
CAM. The eggs treated with BF-PG showed 32.17 ± 0.65 average number of vessels on 
CAM and the average number of blood vessels found in group of eggs treated with AF-PG 
showed 28.67 ± 0.66. Based on the angiogenesis inhibitory effect of fractions from EEPG on 
vascularisation in chick chorioallantoic membrane (CAM) model, the ethyl acetate fraction 
which showed a significant inhibitory effect was selected to study the effect on glucose 
induced vascular changes in CAM model.
 
The morphological changes in vessels were examined in CAM. There is no incidence 
of morphological changes in group I normal vehicle treated eggs. In hyperglycaemia induced 
group II eggs, microvascular abnormalities including vascular leakage with haemorrhagic 
spots (microaneurysms), proliferation of new vessels (neovascularization), superficial white 
lesions were observed. The incidence of vascular defects was 100 % in group II glucose 
induced eggs. Group III hyperglycaemia induced eggs treated with 100 µg EAF-PG showed 
normal vascular architecture with no incidence of vascular abnormality (Fig.26).    
The average number of vessels in group II glucose induced were significantly more 
(p<0.001) compared to group I sterile water treated. The average number of vessels in group 
II were 54.00 ± 1.23 compared to sterile water treated group with vessel number 31.00 ± 
0.96. The group III glucose induced eggs treated with EAF-PG showed an average number of 
Chapter – VI                                                                                      Results and Discussion 
 
Department of Pharmacology                                      The Erode College of Pharmacy    
103 
vessel of 42.33 ± 1.05 which was significantly less (p<0.01) compared to group II eggs 
(Table.13 and figure. 23)  
The blood glucose levels were measured in blood samples taken from CAM vessels. 
The blood glucose level of group I normal eggs (vehicle treated) were 73.50 ± 1.25mg/dl. 
The blood samples taken from CAM vessels of group II eggs showed an average blood 
glucose levels of 304.8 ± 2.85 mg/dl which was significantly high (p<0.001) compared to 
group I vehicle treated eggs. The blood glucose level of group III glucose induced eggs 
treated with EAF-PG 100 µg showed an average blood glucose glucose level of 117.0 ± 2.63 
mg/dl which was significantly less compared to group II glucose induced eggs. There was a 
significant decrease in blood glucose level between group II and group III eggs (Table.14 and 
Figure.28) 
DISCUSSION  
Angiogenesis is the physiologic condition characterized by the growth of new blood 
vessels originated from preexisting ones. The angiogenic process follows several steps: first 
of all, a number of angiogenic growth factors activate the receptors present on resident 
endothelial cells. Once activated, the endothelial cells begin to release specific enzymes 
called proteases that degrade the basement membrane, finally allowing endothelial cells to 
leave the original (parental) vessel wall. At this stage, endothelial cells proliferate into the 
surrounding matrix, taking advantage of adhesion molecules called integrins followed by 
proliferation of the endothelial cells, vessels elongation, vessels branching, vasodilatation, 
formation of basement membrane, acquisition of pericyte, and re-modelling (West and 
Burbridge, 2009). Angiogenesis may represent a pharmacological target for combating 
diseases characterized by either poor vascularization or hypertrophic vasculature. 
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Antiangiogenic therapies, in particular, are presently employed to fight cancer and other 
malignancies (Tremolada et al. 2012). 
The angiogenic switch takes place when the positive angiogenic factors such as 
VEGF outweigh the negative factors such as endostatin (Folkman, 2002). Therefore, the 
angiogenic switch may result from over production of VEGF. Since angiogenesis is 
indispensable for tumour growth and metastasis, early in 1971, Folkman proposed that the 
growth and metastasis of tumor could be reduced by inhibiting angiogenesis (Folkman, 
1971). Recently more efforts have been concentrated on synthesis or discovery of non-
cytotoxic compounds that have antiangiogenic and anti-neoplastic activity. This treatment 
approach decreases the side effects that accompany the classical chemotherapeutics drugs.  
Concerning the eye, the angiogenic process has to be considered as a pathologic 
phenomenon. There are actually several conditions leading to the formation of abnormal 
neovascularization. Age-related macular degeneration is one of the most important diseases 
characterized by the formation of choroidal new vessel in the macular region finally leading; 
if untreated, to vision loss. The other major disease characterized by abnormal formation of 
retinal vessels is diabetic retinopathy, in particular the so-called proliferative stage of this 
disease (Tremolada et al. 2012). Chronic and sustained hyperglycemia works as a trigger to 
the early alterations that culminate in vascular dysfunction (Capitao and Soares 2016). 
Hyperglycemia can cause diabetic micro- (UK Prospective Diabetes Study (UKPDS) Group) 
and macrovascular complications (Holman et al. 2008) by triggering oxidative stress 
[Brownlee 2001; Paget et al. 1998), forming advanced glycation end products (AGEs) (Paget 
et al. 1998; Basta et al. 2002), increasing the flux of glucose to sorbitol through the polyol 
and hexosamine pathways (Brownlee 2001), activating protein kinase C (PKC) (Ishii et al. 
1998), and provoking inflammation (Shanmugam et al. 2004). More importantly, activation 
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of PKC can induce endothelial cells to release entothelin-1, which is a potent vasoconstrictor 
that may decrease retinal perfusion, and vascular endothelial growth factors (VEGFs) that 
may break down the blood-brain barrier and also lead to neovascularisation (Knot 2003).  
Since angiogenesis is critical for tumor growth and metastasis, abnormal 
neovascularization and vascular dysfunction in diabetic retinopathy, anti-angiogenic and 
vaculoprotective treatments will be a highly promising therapeutic approach. Thus, for over 
last couple of decades, there has been a robust activity aimed towards the discovery of 
angiogenesis inhibitors. More than forty anti-angiogenic drugs are being tested in clinical 
trials all over the world. Many studies have been focused on screening compounds or extracts 
from natural products for antiangiogenic properties (Aisha et al., 2009; Wang et al., 2004).  
With the goal of finding a potent antiangiogenic and vasculoprotective drug, an initiative was 
taken to screen widely known medicinal plant Punica granatum. Encouraged from the 
promising results of previous studies on Punica granatum roots, in this study Punica 
granatum roots were evaluated for anti-angiogenic and vaculoprotective property in 
chorioallantoic membrane model. Since CAM model is used as an effective model for 
investigating angiogenesis, including anti-angiogenic drugs (Richardson and Singh 2003), 
CAM model was selected to study the effect of Punica granatum roots. Crude ethanol extract 
of Punica granatum root were evaluated for angiogenesis modulatory role in chorioallantoic 
membrane. Crude ethanol extract of Punica granatum root at a concentration of 100 µg 
showed a potent inhibition on microvascular formation in developing CAM during 
embryogenesis.  Since crude ethanol extract of Punica granatum showed a potent inhibition 
of angiogenesis in CAM assay model, EEPG was subjected to successive fractionation using 
solvents of increasing polarity (Petroleum ether, chloroform, ethyl acetate, n-butanol, 
aqueous). The fractions obtained were subjected to evaluation for angiogenesis modulatory  
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role in chorioallantoic membrane. From the results, it was observed that ethyl acetate fraction 
at concentration of 100 µg showed a potent in inhibition of angiogenesis in CAM assay. 
Based on the results obtained from chorioallantoic membrane assay, ethyl acetate fraction 
was evaluated for vasculoprotective property against glucose induced vascular changes in 
CAM model. Hyperglycaemia was induced by single intravitellus injection of 5 mg glucose/g 
whole egg. On day 12 of incubation, blood glucose level was measured in the samples taken 
from the CAM vessel using Accu-check glucometer and the blood vessels were inspected for 
any vascular change/abnormalities. A significant increase in blood glucose was noted in 
glucose induced eggs with microvascular abnormalities including vascular leakage with 
haemorrhagic spots (microaneurysms), proliferation of new vessels (neovascularization), 
superficial white lesions were observed. Ethyl acetate fraction at concentration of 100 µg 
showed a significant protection against glucose induced microvascular abnormalities with a 
significant decrease in blood glucose level. The proliferation of new vessels 
(neovascularization) in glucose induced eggs is might be due to vascular occlusion that is 
responsible for ischemia. Ischemia, via hypoxia-inducible transcription factors (HIF-1 α and -
2α), will trigger a coordinated response of angiogenesis by inducing the expression of growth 
factors, such as the vascular endothelial growth factor (VEGF), the angiopoietins, and the 
transforming growth factor-β1 (TGF-β1) and their receptors, and by decreasing expression of 
natural inhibitors (e.g., thrombospondin-1, pigment epithelium-derived factor) (Larger et al. 
2004). Due to fragile and having thin wall, these newly formed blood vessels are leaky, 
which leak the blood on the surface. Also in hyperglycemic there will be increase in 
diacylglycerol generation (DAG), advanced glycosylation end product (AGE) and free 
radical generation which activate PKC receptor by DAG-PKC pathway cause capillary 
degeneration and vascular permeability (Brownlee 2001). The significant protection excerted 
by Punica granatum root against glucose induced vascular abnormality in CAM is might be 
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due to anti-angiogenic and anti-oxidant nature. All parts of the pomegranate were reported 
to contain high levels of ellagitannins. Pomegranate root was reported root to contain high 
levels of ellagitannins. Upon consumption, ellagitannins are hydrolyzed to ellagic acid which 
is reported to be anti-angiogenic. The root part is also rich in punicalin and punicalagin. Both 
punicalagin and punicalin can be hydrolyzed to ellagic acid, a natural phenol with high 
antioxidant activity that can prevent the advanced glycosylation end product (AGE) and free 
radical generation that cause capillary degeneration and vascular permeability. Since anti-
oxidants are well known potent anti-angiogenic (Lobo et al. 2010).  The potency of EAF-PG 
in inhibiting new blood vessel development could be contributed to its significant antioxidant 
behaviour. One of the potent angiogenic agents is transforming growth factor alpha TGFα; 
antioxidant agents can inhibit TGFα expression as one aspect of their ability to inhibit 
angiogenesis (Teo and HO, 2013). It is also suggested that the extract might contain active 
constituents that repress the expression of VEGF and VEGF like growth factors thereby 
inhibiting the formation of blood vessels.  
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SUMMARY AND CONCLUSION 
The effect of punica granatum roots on angiogenesis and vasoprotection was 
evaluated by chorioallantoic membrance (CAM) model. Powdered Punica granatum roots 
were extracted with ethanol by hot continuous extraction method. The crude ethanol extract 
of Punica granatum was subjected to preliminary photochemical examination and 
quantitative analysis. The free radical scavenging activity of extract was evaluated by DPPH 
radical scavenging and nitric oxide scavenging activity. It was observed that the extract was 
rich in alkaloids, flavonoids, tannins, saponins, glycoside and possessed a potent free radical 
scavenging activity. 
The extract was screened for angiogenesis modulation in chorioallantoic membranel. 
In CAM model, a significant decrease in average number of blood vessels was noted in 
extract treated group compared to vehicle control eggs. The extract was subjected to 
fractionation using solvents of increasing potency and the fractions were subjected to 
evaluation of anti-angiogenesis activity in CAM. Among the fractions, the ethyl acetate 
fraction showed a potent angiogenesis inhibition compared to vehicle control. Based on these 
results the ethyl acetate fraction was evaluated against glucose induced vascular changed in 
CAM model. To induce hyperglycemia in developing embryo, a single intravitellus injection 
of 5 mg glucose/g whole egg was introduced. The treatment groups received ethyl acetate 
fraction and 5 mg glucose/g whole egg. On day 12 of incubation, the blood glucose levels 
were measured in blood samples taken from CAM vessels and vascular changes were 
examined in CAM.  Hyperglycaemia with vascular leakage, haemorrhagic spots 
(microaneurysms), proliferation of new vessels (neovascularization), superficial lesions were 
spotted in untreated eggs. Ethyl acetate fraction 100 µg showed a significant protection 
against glucose induced microvascular abnormalities with a significant decrease in blood 
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glucose level and reduced average number of blood vessels. These findings demonstrate the 
anti-angiogenic and vasculoprotective effect of Punica granatum  against hyperglycaemia 
induced vascular changes in CAM model.  
In conclusion, root extract of Punica granatum possess a significant angiogenesis 
inhibition in chorioallantoic membrane assay and vasuloprotective effect in glucose induced 
vascular change.  The possible mechanism of antiangiogenesis and vasoprotective actions are 
might be due to the presence of active principles that possess a potent antioxidant property of 
roots, as antioxidants are potent inhibitors of angiogenesis and might be due to the presence 
of inhibitors that repress the expression of VEGF and VEGF like growth factors thereby 
inhibiting the formation of new blood vessels and maintaining a vascular stability by 
inhibiting capillary degeneration and permeability. Thus the isolation of antiangiogenic active 
principle from Punica granatum roots could bring hope to millions of sufferers with cancer 
and diabetic retinopathy. Further work is in progress to identify the bioactive compounds and 
delineate the underlying mechanism of antiangiogenesis and vasoprotection. 
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